(19)
(11)EP 3 307 726 B1

(12)EUROPEAN PATENT SPECIFICATION

(45)Mention of the grant of the patent:
20.05.2020 Bulletin 2020/21

(21)Application number: 16735586.6

(22)Date of filing:  10.06.2016
(51)Int. Cl.: 
C07D 401/12  (2006.01)
A61K 31/4439  (2006.01)
A61K 31/435  (2006.01)
A61P 35/00  (2006.01)
(86)International application number:
PCT/EP2016/063293
(87)International publication number:
WO 2016/198597 (15.12.2016 Gazette  2016/50)

(54)

2-OXO-1,2-DIHYDROPYRIDINE-3-CARBOXAMIDE COMPOUNDS AND THEIR USE AS INHIBITORS OF PDK1

2-OXO -1,2-DIHYDROPYRIDIN-3-CARBOXAMID-VERBINDUNGEN UND IHRE VERWENDUNG ALS PDK1-HEMMER

COMPOSÉS DE 2-OXO-1,2-DIHYDROPYRIDINE-3-CARBOXAMIDE ET LEUR UTILISATION À TITRE D'INHIBITEURS DE PDK1


(84)Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)Priority: 11.06.2015 IT UB20150999

(43)Date of publication of application:
18.04.2018 Bulletin 2018/16

(73)Proprietor: International Society for Drug Development S.r.l.
20135 Milano (IT)

(72)Inventors:
  • SESTITO, Simona
    88064 Chiaravalle Centrale (IT)
  • DANIELE, Simona
    56121 Pisa (IT)
  • MARTINI, Claudia
    56126 Pisa (IT)
  • RAPPOSELLI, Simona
    55012 Capannori (IT)
  • PURICELLI, Guido
    20148 Milano (IT)

(74)Representative: Cattaneo, Elisabetta et al
Notarbartolo & Gervasi S.p.A Corso di Porta Vittoria, 9
20122 Milano
20122 Milano (IT)


(56)References cited: : 
WO-A1-2010/065384
WO-A2-2008/005457
  
  • K. NAGASHIMA ET AL: "Genetic and Pharmacological Inhibition of PDK1 in Cancer Cells: CHARACTERIZATION OF A SELECTIVE ALLOSTERIC KINASE INHIBITOR", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 286, no. 8, 25 February 2011 (2011-02-25), pages 6433-6448, XP055212624, ISSN: 0021-9258, DOI: 10.1074/jbc.M110.156463 cited in the application
  • SESTITO SIMONA ET AL: "Locking PDK1 in DFG-out conformation through 2-oxo-indole containing molecules: Another tools to fight glioblastoma", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, EDITIONS SCIENTIFIQUE ELSEVIER, PARIS, FR, vol. 118, 20 April 2016 (2016-04-20), pages 47-63, XP029562541, ISSN: 0223-5234, DOI: 10.1016/J.EJMECH.2016.04.003
  • Mathéa Pietri ET AL: "PDK1 decreases TACE-mediated [alpha]-secretase activity and promotes disease progression in prion and Alzheimer's diseases", Nature Medicine, vol. 19, no. 9, 18 August 2013 (2013-08-18), pages 1124-1131, XP055639849, New York ISSN: 1078-8956, DOI: 10.1038/nm.3302
  • KHORAMI HOSSEINI, MALAYSIA UNIVERSITI PUTRA, MOVAHEDI ARIYO, SOKHINI MOHD, MUTALIB ABDUL, KHAZA, HUZWAH AI, MUTALIB ABD: "PI3K/AKT pathway in modulating glucose homeostasis and its alteration in diabetes", ANNALS OF MEDICAL AND BIOMEDICAL SCIENCES, vol. 1, no. 2, 22 October 2015 (2015-10-22), pages 46-55,
  
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).


Description

FIELD OF INVENTION



[0001] The invention concerns 2-oxo-1,2-dihydropyridine-3-carboxamide compounds and their use as inhibitors and/or modulators of PDK1.

STATE OF THE ART



[0002] The Pl3K/PDK1/Akt signaling axis is centrally involved in inhibition of apoptosis and stimulation of cell proliferation and it has been estimated that at least 50% of all cancer types are related to deregulation of this signaling pathway.

[0003] Due to its key function as regulator of cell survival and metabolism, the dysregulation of this pathway is manifested in several human pathologies including cancers and neurodegenerative diseases. Phosphoinositide-dependent kinase (PDK1) acts as one of the main mediators of the pathway. PDK1 is a serine/threonine protein kinase that plays a key role in regulating cell growth, proliferation, and survival through both Akt-dependent and Akt-independent mechanisms. The Akt-dependent pathway is characterized by the implication of downstream proteins like mTOR, Ras and GSK, all controlled by Akt. The Akt-independent signal acts via PLCγ1, a phospholipase implicated in metastasis.

[0004] The phosphorylation and, therefore, activation of multiple substrates that seem to be constitutively active in tumor tissue (such as AKT, S6K, SGK, RSK and PKC isoforms) may explain the influence of this kinase on a variety of cellular processes including proliferation, migration and survival.

[0005] For these reasons, PDK1 also known as "master kinase" of the AGC kinases has attracted considerable interest as an anticancer drug target. However, although there have been done huge efforts in discovering specific molecules targeting PI3K and Akt, PDK1 has been rather overlooked. Recently the increasing interest in this kinase prompted many research groups to work in this direction, thus publishing and patenting several series of molecules able to inhibit this important node of the Pl3K/PDK1/Akt.

[0006] PDK1 plays a pleiotropic role in growth and development. Recent findings revealed that elevated activation of PDK1 induces tumorigenesis by enhancing cell proliferation and inhibiting apoptosis. In addition, increasing evidence show that PDK1 plays a pivotal role in cell migration and metastasis. Its role in these processes was proved in different cell types and organisms including endothelial cells, smooth muscle cells, T lymphocytes, neutrophils and several tumour cell lines such as breast, glioblastoma (Signore, M., et al., Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo. Cell death & disease, 2014. 5(5): p. e1223) and pancreatic cancers.

[0007] In WO2008/005457 new pyridinonyl compounds are described having PDK1 inhibition activity as demonstrated for some prepared compounds in vitro. The same compounds were also studied on cellular lines and the results are reported in Nagashima, K., et al., Genetic and Pharmacological Inhibition of PDK1 in Cancer Cells CHARACTERIZATION OF A SELECTIVE ALLOSTERIC KINASE INHIBITOR. Journal of Biological Chemistry, 2011. 286(8): p. 6433-6448. Even if some compounds were claimed as PDK1 inhibitors in WO2008/005457, they do not significantly inhibit cell growth on standard tissue cell culture, specifically on PC3 prostate cancer lines.

[0008] There is a great need for efficacious inhibitors against PDK1 enzyme.

SUMMARY OF THE INVENTION



[0009] The above object has been achieved by a 2-oxo-1,2-dihydropyridine-3-carboxamide compound of Formula (I)

wherein

m is 0 or 1

n is 0 or 1

B is CH-D, where D is selected from the group consisting of thienyl, phenyl, imidazolyl, being D optionally substituted with a halogen; and A is selected from the group consisting of (-NH-CO-CH2-), (-NH-CO-CH(Ph)-), (-NH-CO-CH2-CH2-), (-NH-CO-CH2-CH2-CH2-) and (-NH-CO-Ph-),

or a pharmaceutical salt thereof for use in the treatment of pathologies requiring the use of an inhibitor of PDK1 enzyme.

[0010] In another aspect the invention concerns a new 2-oxo-1,2-dihydropyridine-3-carboxamide compound of Formula (II)

wherein

n is 0 or 1

B is CH-D, where D is selected from the group consisting of thienyl, phenyl, imidazolyl, being D optionally substituted with a halogen; and A is selected from the group consisting of (-NH-CO-CH2-), (-NH-CO-CH(Ph)-) (-NH-CO-CH2-CH2-) (-NH-CO-CH2-CH2-CH2-) and (-NH-CO-Ph-),

or a pharmaceutical salt thereof.

[0011] In another aspect the invention concerns a compound of Formula (II) for use as a medicament.

[0012] In a further aspect the invention concerns a pharmaceutical composition comprising a compound of Formula (II) and a pharmaceutically acceptable carrier.

[0013] In a still further aspect the invention concerns a compound of Formula (II) for use in the treatment of pathologies requiring the use of a PDK1-inhibitor.

[0014] The pathologies that require a PDK1 enzyme inhibitor are diabetes, neurodegenerative diseases such as Alzheimer's and Prion Diseases, and tumours such as breast, and pancreatic cancers and glioblastoma. Preferably such pathology is a cancer, more preferably glioblastoma (GBM).

[0015] In this invention a compound of Formula (I) or Formula (II) may exist as R and S enantiomers and as racemic mixture. This invention includes in its scope of protection all the possible isomers and racemic mixtures. Wherever should be present further symmetry centers, this invention includes all the possible diastereoisomers and relative mixtures as well.

DESCRIPTION OF THE FIGURES



[0016] 

Figure 1 illustrates the inhibition of U87MG cell proliferation after 24 h of incubation with compounds of the invention;

Figure 2 illustrates the inhibition of U87MG cell proliferation after 72 h of incubation with compounds of the invention;

Figure 3 shows the effects of PDK1 inhibitors of the invention on the induction of U87MG apoptosis using Annexin V-staining protocol;

Figure 4 shows the effects of PDK1 inhibitors of the invention on the induction of U87MG apoptosis as percentage of apoptotic cells versus the total number of cells;

Figure 5 shows the effects of the compounds of the invention on PDK1 activity in U87 MG cells;

Figure 6 shows micrographs in the evaluation of effects of the PDK1 inhibitors of the invention on wound healing migration;

Figure 7 shows gap area measurements in the evaluation of effects of the PDK1 inhibitors of the invention on wound healing migration;

Figure 8 shows the effects of the treatment of the compounds of the invention on GSC proliferation after four days;

Figure 9 shows the effects of the treatment of the compounds of the invention on GSC proliferation after seven days;

Figure 10 shows the effects of PDK1 inhibitors of the invention on GSC apoptosis using Annexin V-staining protocol;

Figure 11 shows the effects of PDK1 inhibitors of the invention on GSC apoptosis as percentage of apoptotic cells versus the total number of cells; and

Figure 12 shows the effects of PDK1 inhibitors of the invention on GSC by ELISA assays.


DETAILED DESCRIPTION OF THE INVENTION



[0017] The invention hence concerns a 2-oxo-1,2-dihydropyridine-3-carboxamide compound of Formula (I)

wherein

m is 0 or 1

n is 0 or 1

A is selected from the group consisting of (-NH-CO-CH2-), (-NH-CO-CH(Ph)-), (-NH-CO-CH2-CH2-), (-NH-CO-CH2-CH2-CH2-) and (-NH-CO-Ph-); and

B is CH-D, where D is selected from the group consisting of thienyl, phenyl, imidazolyl, being D optionally substituted with a halogen,

or a pharmaceutical salt thereof for use in the treatment of pathologies requiring the use of an inhibitor of PDK1 enzyme.

[0018] When m is 0, n is preferably 1.

[0019] When m is 1, n can be 0 or 1.

[0020] Preferably m is 1 and n is 1.

[0021] When m is 1 A is selected from the group consisting of (-NH-CO-CH2-), (-NH-CO-CH(Ph)-), (-NH-CO-CH2-CH2-), (-NH-CO-CH2-CH2-CH2-) and (-NH-CO-Ph-).

[0022] Preferably A is (-NH-CO-CH2-), (-NH-CO-CH2-CH2-), (-NH-CO-CH2-CH2-CH2-) or (-NH-CO-Ph-).

[0023] When n is 1, B is CH-D, where D is selected from the group consisting of thienyl, phenyl, imidazolyl, being D optionally substituted with a halogen.

[0024] Preferably D is imidazolyl, preferably 1H-imidazol-5-yl or 1H-imidazol-2-yl.

[0025] In a preferred embodiment A is (-NH-CO-CH(Ph)-) and D is imidazolyl, preferably 1 H-imidazol-5-yl.

[0026] In a more preferred embodiment A is (-NH-CO-CH2-) and D is imidazolyl, preferably 1H-imidazol-5-yl.

[0027] In a more preferred embodiment A is (-NH-CO-CH2-CH2) and D is imidazolyl, preferably 1H-imidazol-5-yl.

[0028] In a more preferred embodiment A is (-NH-CO-CH2-CH2) and D is imidazolyl, preferably 1H-imidazol-2-yl.

[0029] In a further preferred embodiment A is (-NH-CO-CH2-CH2-CH2-) or (-NH-CO-Ph), more preferably D is imidazolyl, still more preferably 1H-imidazol-5-yl.

[0030] The preferred compound for the use as PDK1 inhibitor is one of the compounds reported in the Table below.
StructureIUPAC name


JJ31 (Z)-N-(3-((1H-imidazol-5-yl)methylene)-2-oxoindolin-5-yl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide


IB32 1-(3,4-difluorobenzyl)-2-oxo-N-(2-oxo-2-((2-oxoindolin-5-yl)amino)ethyl)-1,2-dihydropyridine-3-carboxamide


IB36 (E/Z)-1-(3,4-difluorobenzyl)-2-oxo-N-(2-oxo-2-((2-oxo-3-(thiophe-2-ylmethylene)indolin-5-yl)amino)ethyl)-1,2-dihydropyridine-3-carboxamide


IB35 (Z)-N-(2-((3-((1H-imidazol-5-yl)methylene)-2-oxoindolin-5-yl)amino)-2-oxoethyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-di hydro pyridi ne-3-carboxamide


SA16 (Z)-(R)-N-(2-((3-((1H-imidazol-5-yl)methylene)-2-oxoindolin-5-yl)amino)-2-oxo-1-phenylethyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide


SA23 (Z)-(R)-N-(2-((3-((1H-imidazol-2-yl)methylene)-2-oxoindolin-5-yl)amino)-2-oxo-1-phenylethyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide


DD22 (E/Z)-1-(3,4-difluorobenzyl)-2-oxo-N-(3-oxo-3-((2-oxo-3-(thiophen-2-ylmethylene)indolin-5-yl)amino)propyl)-1,2-dihydropyridine-3-carboxamide


DD21 (Z)-N-(3-((3-((1H-imidazol-5-yl)methylene)-2-oxoindolin-5-yl)amino)-3-oxopropyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide


DD23 (E/Z)-1-(3,4-difluorobenzyl)-N-(3-((3-(4-fluorobenzylidene)-2-oxoindolin-5-yl)amino)-3-oxopropyl)-2-oxo-1,2-dihydropyridine-3-carboxamide


DD25 (Z/E)-N-(3-((3-((1H-imidazol-2-yl)methylene)-2-oxoindolin-5-yl)amino)-3-oxopropyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide


DD40 (Z)-N-(3-((3-((1H-imidazol-5-yl)methylene)-2-oxoindolin-5-yl)carbamoyl)phenyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide


DD41 (E/Z)-1-(3,4-difluorobenzyl)-2-oxo-N-(3-((2-oxo-3-(thiophen-2-ylmethylene)indolin-5-yl)carbamoyl)phenyl)-1,2-dihydropyridine-3-carboxamide


DF8 (Z)-N-(4-((3-((1H-imidazol-5-yl)methylene)-2-oxoindolin-5-yl)amino)-4-oxobutyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide


DF9 (E/Z)-1-(3,4-difluorobenzyl)-2-oxo-N-(4-oxo-4-((2-oxo-3-(thiophen-2-ylmethylene)indolin-5-yl)amino)butyl)-1,2-dihydropyridine-3-carboxamide


[0031] More preferably the compound of Formula (I) is selected from the group (Z)-N-(2-((3-((1H-imidazol-5-yl)methylene)-2-oxoindolin-5-yl)amino)-2-oxoethyl)-1-(3,4-difluorobenzyl)-2-oxo-1 ,2-dihydropyridine-3-carboxamide, (Z)-(R)-N-(2-((3-((1 H-imidazol-5-yl)methylene)-2-oxoindolin-5-yl)amino)-2-oxo-1-phenylethyl)-1-(3,4-difluorobenzyl)-2-oxo-1 ,2-dihydropyridine-3-carboxamide, (Z)-(R)-N-(2-((3-((1 H-imidazol-2-yl)methylene)-2-oxoindolin-5-yl)amino)-2-oxo-1 -phenylethyl)-1 -(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide, (Z)-N-(3-((3-((1H-imidazol-5-yl)methylene)-2-oxoindolin-5-yl)carbamoyl)phenyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide, (Z)-N-(4-((3-((1 H-imidazol-5-yl)methylene)-2-oxoindolin-5-yl)amino)-4-oxobutyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide and (Z)-N-(3-((3-((1 H-imidazol-5-yl)methylene)-2-oxoindolin-5-yl)amino)-3-oxopropyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-di hydropyridine-3-carboxamide.

[0032] Still more preferably, the compound of Formula (I) is (Z)-N-(2-((3-((1 H-imidazol-5-yl)methylene)-2-oxoindolin-5-yl)amino)-2-oxoethyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide.

[0033] Preferred compounds are also (Z)-N-(4-((3-((1 H-imidazol-5-yl)methylene)-2-oxoindolin-5-yl)amino)-4-oxobutyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide and (Z)-N-(3-((3-((1 H-imidazol-5-yl)methylene)-2-oxoindolin-5-yl)amino)-3-oxopropyl)-1-(3,4-difluorobenzyl)-2-oxo-1 ,2-dihydropyridine-3-carboxamide. In another aspect the invention relates a 2-oxo-1,2-dihydropyridine-3-carboxamide compound of Formula (II)

wherein

n is 0 or 1

B is CH-D, where D is selected from the group consisting of thienyl, phenyl, imidazolyl, being D optionally substituted with a halogen; and A is selected from the group consisting of (-NH-CO-CH2-), (-NH-CO-CH(Ph)-) (-NH-CO-CH2-CH2-), (-NH-CO-CH2-CH2-CH2-) and (-NH-CO-Ph-),

or a pharmaceutical salt thereof.

n is 0 or 1, more preferably n is 1.

A is selected from the group consisting of (-NH-CO-CH2-), (-NH-CO-CH(Ph)-) (-NH-CO-CH2-CH2-), (-NH-CO-CH2-CH2-CH2-) and (-NH-CO-Ph-). Preferably A is (-NH-CO-CH2-), (-NH-CO-CH2-CH2-CH2-), (-NH-CO-CH2-CH2-) or (-NH-CO-Ph-). In a more preferred embodiment n is 1 and A is selected from the group consisting of (-NH-CO-CH2-), (-NH-CO-CH2-CH2-) (-NH-CO-CH2-CH2-CH2-) and (-NH-CO-Ph-).

When n is 1, B is CH-D, where D is selected from the group consisting of thienyl, phenyl, imidazolyl, being D optionally substituted with a halogen.



[0034] Preferably D is imidazolyl.

[0035] In a preferred embodiment A is (-NH-CO-CH(Ph)-) and D is imidazolyl, preferably 1 H-imidazol-5-yl.

[0036] In a more preferred embodiment A is (-NH-CO-CH2-) and D is imidazolyl, preferably 1H-imidazol-5-yl.

[0037] In a more preferred embodiment A is (-NH-CO-CH2-CH2) and D is imidazolyl, preferably 1H-imidazol-5-yl.

[0038] The preferred compound is one of the compounds reported in the Table below.
StructureIUPAC name


IB32 1-(3,4-difluorobenzyl)-2-oxo-N-(2-oxo-2-((2-oxoindolin-5-yl)amino)ethyl)-1,2-dihydropyridine-3-carboxamide


IB36 (E/Z)-1-(3,4-difluorobenzyl)-2-oxo-N-(2-oxo-2-((2-oxo-3-(thiophe-2-ylmethylene)indolin-5-yl)amino)ethyl)-1,2-dihydropyridine-3-carboxamide


IB35 (Z)-N-(2-((3-((1H-imidazol-5-yl)methylene)-2-oxoindolin-5-yl)amino)-2-oxoethyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydro pyridine-3-carboxamide


SA16 (Z)-(R)-N-(2-((3-((1H-imidazol-5-yl)methylene)-2-oxoindolin-5-yl)amino)-2-oxo-1-phenylethyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide


SA23 (Z)-(R)-N-(2-((3-((1H-imidazol-2-yl)methylene)-2-oxoindolin-5-yl)amino)-2-oxo-1-phenylethyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide


DD22 (E/Z)-1-(3,4-difluorobenzyl)-2-oxo-N-(3-oxo-3-((2-oxo-3-(thiophen-2-ylmethylene)indolin-5-yl)amino)propyl)-1,2-dihydropyridine-3-carboxamide


DD21 (Z)-N-(3-((3-((1H-imidazol-5-yl)methylene)-2-oxoindolin-5-yl)amino)-3-oxopropyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide


DD23 (E/Z)-1-(3,4-difluorobenzyl)-N-(3-((3-(4-fluorobenzylidene)-2-oxoi ndolin-5-yl)amino)-3-oxopropyl)-2-oxo-1,2-dihydropyridine-3-carboxamide


DD25 (Z/E)-N-(3-((3-((1H-imidazol-2-yl)methylene)-2-oxoindolin-5-yl)amino)-3-oxopropyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide


DD40 (Z)-N-(3-((3-((1H-imidazol-5-yl)methylene)-2-oxoindolin-5-yl)carbamoyl)phenyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide


DD41 (E/Z)-1-(3,4-difluorobenzyl)-2-oxo-N-(3-((2-oxo-3-(thiophen-2-ylmethylene)indolin-5-yl)carbamoyl)phenyl)-1,2-dihydropyridine-3-carboxamide


DF8 (Z)-N-(4-((3-((1H-imidazol-5-yl)methylene)-2-oxoindolin-5-yl)amino)-4-oxobutyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide


DF9 (E/Z)-1-(3,4-difluorobenzyl)-2-oxo-N-(4-oxo-4-((2-oxo-3-(thiophen-2-ylmethylene)indolin-5-yl)amino)butyl)-1,2-dihydropyridine-3-carboxamide


[0039] More preferably the compound of Formula (II) is selected from the group (Z)-N-(2-((3-((1H-imidazol-5-yl)methylene)-2-oxoindolin-5-yl)amino)-2-oxoethyl)-1-(3,4-difluorobenzyl)-2-oxo-1 ,2-dihydropyridine-3-carboxamide, (Z)-(R)-N-(2-((3-((1 H-imidazol-5-yl)methylene)-2-oxoindolin-5-yl)amino)-2-oxo-1 -phenylethyl)-1 -(3,4-difluorobenzyl)-2-oxo-1 ,2-dihydropyridine-3-carboxamide, (Z)-(R)-N-(2-((3-((1H-imidazol-2-yl)methylene)-2-oxoindolin-5-yl)amino)-2-oxo-1 -phenylethyl)-1 -(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide, (Z)-N-(3-((3-((1H-imidazol-5-yl)methylene)-2-oxoindolin-5-yl)carbamoyl)phenyl)-1-(3,4-difluorobenzyl)-2-oxo-1 ,2-dihydropyridine-3-carboxamide, (Z)-N-(4-((3-((1 H-imidazol-5-yl)methylene)-2-oxoindolin-5-yl)amino)-4-oxobutyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide and (Z)-N-(3-((3-((1H-imidazol-5-yl)methylene)-2-oxoindolin-5-yl)amino)-3-oxopropyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide.

[0040] Still more preferably, the compound of Formula (II) is (Z)-N-(2-((3-((1 H-imidazol-5-yl)methylene)-2-oxoindolin-5-yl)amino)-2-oxoethyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide.

[0041] Preferred compounds are also (Z)-N-(3-((3-((1H-imidazol-5-yl)methylene)-2-oxoindolin-5-yl)carbamoyl)phenyl)-1-(3,4-difluorobenzyl)-2-oxo-1 ,2-dihydropyridine-3-carboxamide, or (Z)-N-(4-((3-((1 H-imidazol-5-yl)methylene)-2-oxoindolin-5-yl)amino)-4-oxobutyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide or (Z)-N-(3-((3-((1 H-imidazol-5-yl)methylene)-2-oxoindolin-5-yl)amino)-3-oxopropyl)-1-(3,4-difluorobenzyl)-2-oxo-1 ,2-dihydropyridine-3-carboxamide. The compounds of the invention can be prepared by using processes, easy to scale-up and avoiding lengthy and expensive preparation steps thus obtaining high yield of a stable pharmaceutical grade compound as it will be evident from the experimental part of the present description.

[0042] The compounds of the invention of Formulas (I) and (II) as such or a pharmaceutical salt thereof could be used in medicine in particular as inhibitor of PDK1 enzyme.

[0043] In another aspect, the present invention provides a pharmaceutical composition comprising a compound of Formula (I) and/or Formula (II) and a pharmaceutically acceptable excipient, for example a carrier. The pharmaceutical composition can also comprise a known PDK1 inhibitor compound.

[0044] The compounds of the invention of Formula (I) and of Formula (II) can be administered alone or can be coadministered to the patient. Coadministration is meant to include simultaneous or sequential administration of the compounds individually or in combination (more than one compound). Thus, the preparation can also be combined, when desired, with other active substances.

[0045] They could be used in combination with a pharmaceutically acceptable carrier and optionally with suitable excipients to obtain pharmaceutical compositions. The term "pharmaceutically acceptable carrier" means solvents, carrier agents, diluting agents, and the like which are used in the administration of compounds of the invention.

[0046] Such pharmaceutical compositions can be administered by parenteral, oral, buccal, sublingual, nasal, rectal, topical or transdermal administration. Compositions of the invention suitable for the oral administration will be conveniently discrete units such as tablets, capsules, cachet, powders or pellets or as liquid suspension.

[0047] The tablet can contain also suitable excipients routinely used in pharmaceutical field such as pre-gelatinized starch, microcrystalline cellulose, sodium glycolate starch, talc, lactose, magnesium stearate, sucrose, stearic acid, mannitol. Compositions for parental administration may conveniently include sterile preparations.

[0048] Composition for topical administration may conveniently be formulated as creams, pastes, oils, ointments, emulsions, foams, gels, drops, spray solutions and transdermal patches.

[0049] The compounds of the invention can be used as a medicament in the treatment of pathologies which require an inhibitor of PDK1 enzyme such as cancers, preferably in the treatment of glioblastoma (GBM).

[0050] The compounds of Formula (I) and Formula (II) showed to inhibit the PDK1 enzyme with IC50 values in the range of nM to µM as it will be evident from the experimental part of the description.

[0051] The ranking of IC50 value on recombinant PDK1 reflected the affinity ranking towards glioblastoma cell lines, thus confirming that the antiproliferative activity is mediated by PDK1.

[0052] Advantageously the preferred compounds (Z)-N-(2-((3-((1 H-imidazol-5-yl)methylene)-2-oxoindolin-5-yl)amino)-2-oxoethyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide, (Z)-(R)-N-(2-((3-((1 H-imidazol-5-yl)methylene)-2-oxoindolin-5-yl)amino)-2-oxo-1-phenylethyl)-1-(3,4-difluorobenzyl)-2-oxo-1 ,2-dihydropyridine-3-carboxamide, (Z)-(R)-N-(2-((3-((1 H-imidazol-5-yl)methylene)-2-oxoindolin-2-yl)amino)-2-oxo-1-phenylethyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide,(Z)-N-(3-((3-((1H-imidazol-5-yl)methylene)-2-oxoindolin-5-yl)carbamoyl)phenyl)-1-(3,4-difluorobenzyl)-2-oxo-1 ,2-dihydropyridine-3-carboxamide, (Z)-N-(4-((3-((1 H-imidazol-5-yl)methylene)-2-oxoindolin-5-yl)amino)-4-oxobutyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide and (Z)-N-(3-((3-((1 H-imidazol-5-yl)methylene)-2-oxoindolin-5-yl)amino)-3-oxopropyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide inhibited PDK1 constitutive activity in glioblastoma cells; as a result, the compounds of Formula (II) decreased cell viability, and triggered apoptosis. Moreover, the inhibition of cell viability was long-lasting. In the wound scratch assay as it will be clear below, PDK1 inhibitors showed to significantly inhibit cell migration, both after 6 h and 24 h from the scratch. These results confirmed that a PDK1 inhibition leads to a suppression of tumour cell migration.

[0053] Finally, the compounds of Formulas (I), and preferably of Formula (II), still more preferably the preferred compounds (Z)-N-(2-((3-((1H-imidazol-5-yl)methylene)-2-oxoindolin-5-yl)amino)-2-oxoethyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydro pyridine-3-carboxamide, (Z)-(R)-N-(2-((3-((1H-imidazol-5-yl)methylene)-2-oxoindolin-5-yl)amino)-2-oxo-1-phenylethyl)-1 -(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide, (Z)-(R)-N-(2-((3-((1H-imidazol-5-yl)methylene)-2-oxoindolin-2-yl)amino)-2-oxo-1 -phenylethyl)-1 -(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (Z)-N-(3-((3-((1H-i midazol-5-yl)methylene)-2-oxoindolin-5-yl)carbamoyl)phenyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide, and (Z)-N-(4-((3-((1H-imidazol-5-yl)methylene)-2-oxoindolin-5-yl)amino)-4-oxobutyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide were characterized in glioma stem cells (GSCs) isolated from glioblastoma cells. The obtained results indicated that compounds induced a time- and concentration-dependent inhibition of GSC proliferation and triggered apoptosis, thus confirming that PDK1 inhibitors are capable to block GSC proliferation.

[0054] The invention will be now detailed by means of the following examples relating to the preparation of some invention compounds and to the evaluation of their activity against PDK1 receptor.

EXPERIMENTAL PARTS


Preparation of the compounds of Formulas (I) and (II)



[0055] Commercial grade anhydrous solvents were used without further drying. Commercially available chemicals were purchased from Sigma-Aldrich or Alfa Aesar and used without further purification. Evaporation was performed in vacuum (rotating evaporator). Anhydrous Na2SO4 was always used as the drying agent.

[0056] Flash chromatography was performed on Merck 60 Å high-purity grade silica gel (0.40-63 µm). Reactions were followed by TLC, performed on Merck aluminium silica gel (60 F254) sheets. Spots were viewed under a UV lamp (254 nm) or with the aid 10% phosphomolybdic acid in EtOH. Melting points were determined with a Kofler hot-bench apparatus and were not corrected.

[0057] Hydrogenation reactions were performed through HG 2000 CLAIND® hydrogen generator. Microwave reaction were performed using CEM Discover® LabMateTM Microwave. Celite® 545 was used as filter agent.
1H, 13C and 19F NMR spectra were obtained using a Bruker Avance 400 spectrometer and were recorder at 400, 101 and 376 MHz, respectively. 1H NMR [t=373K] was recorded at 250 MHz on Bruker Avance II 250 spectrometer.

[0058] Chemical shifts are reported in parts per million (ppm) δ values, downfield from the internal reference tetramethylsilane (TMS) and referenced from solvent resonance as the internal standard: deuterochloroform [δ 7.26 (1H spectra), δ 77.16 (13C spectra)]; deuterodimethylsulfoxide [δ 2.50 (1H spectra), δ 39.52 (13C spectra)]; deuteroacetonitrile [δ 1.94 (1H spectra)]. Coupling constants J are reported in hertz (Hz). 19F and 13C NMR spectra are 1H decoupled. 19F NMR spectra are unreferenced, corrected from Trifluoroacetic Acid (TFA) as external standard (-76.2 ppm).

[0059] Signal patterns are indicated as follows: singlet (s), doublet (d), triplet (t), double-doublet (dd), double-triplet (dt), multiplet (m), broad singlet (br s), broad doublet (br d) and broad triplet (br t).

[0060] When the amide nitrogen bears two substituents, the 1H NMR spectra show the presence of two different rotamers in equilibrium.

[0061] The elemental compositions of the compounds (C, H, N) agreed to within (±) 0.4% of the theoretical values. When the elemental analysis is not included, compounds were used in the next step without further purification.

[0062] Abbreviations: TBTU= N,N,N',N'-Tetramethyl-O-(benzotriazol-1-yl)uronium tetrafluoroborate; DIPEA= N,N-Diisopropylethylamine; DMF= N,N-Dimethylformamide; CDI= N,N'-carbonyldiimidazole; TFA= Trifluoroacetic acid; NaH= Sodium hydride; DCM= dichloromethane

Example 1: Preparation of compound JJ31


(Z)-N-(3-((1H-imidazol-5-yl)methylene)-2-oxoindolin-5-yl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide



[0063] The compound JJ31 was prepared by following Scheme 1

aReagents and Conditions: I) H2, Pd-C 10%, absolute EtOH, r.t., 4h; II) TBTU, DIPEA, dry DMF, 0°C -> r.t., 12h; III) 1H-imidazole-5-carbaldehyde, absolute EtOH, piperidine, 110°C, 4h.

[0064] The catalytic hydrogenation of 5-nitro-oxindole in absolute EtOH in presence of Pd-C 10% gave the amine 2. The condensation of the carboxylic acid 3 with TBTU and DIPEA in dry DMF for 16h, gave compound SST143. Compound 3 was synthesised through alkylation with 3,4-difluoro-benzylbromide of the 2-oxo-pyridine-3-carboxylic acid in presence of NaH 60%. The subsequent condensation of derivative SST143 with 1H-imidazole-5-carbaldehyde, and a catalytic amount of piperidine, gave the corresponding compound of the title. The 3-substituted 2-oxindole may exist as either the Zor E isomer depending on the characteristics of the substituents at the C3 position of the 2-oxindole nucleus. The configurations of the compounds were assigned by analyzing their 1H NMR spectra.

Synthesis of 5-amino-1,3-dihydro-2H-indol-2-one (2).



[0065] The 5-nitro-2-oxindole 1 (1.00 g, 5.61 mmol) was hydrogenated in EtOH (70 mL) in the presence of 10% Pd-C (315 mg, 2.97 mmol) for 4h at room temperature. Then the catalyst was filtered off through Celite, the Celite rinsed with additional EtOH and the solution was evaporated, to give 2 as a brown solid (698 mg, 4.71 mmol, 84% yield).
1H-NMR (400 MHz, DMSO-d6): δ 3.30 (s, 2H, CH2); 4.62 (br s, 2H, NH2); 6.37 (dd, 1H, J = 2.2, 8.2 Hz, Ar); 6.48-6.50 (m, 2H, Ar); 9.90 (br s, 1H, NH) ppm. Anal. Calcd for C8H8N2O: C, 64.85%; H, 5.44%; N 18.91%; Found: C, 65.03%; H, 5.49%; N, 18.83%.

Synthesis of 1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxylic acid (3).



[0066] A stirred suspension of NaH 60% dispersion in mineral oil (206 mg, 5.14 mmol), washed twice with distilled n-hexane and once with Et2O in 2 mL of anhydrous DMF under N2 atmosphere was treated dropwise with a solution containing the 2-hydroxynicotinic acid (600 mg, 4.31 mmol) in 5 mL of anhydrous DMF. The mixture was left under stirring at room temperature for 2h and then 3,4-difluoro-benzylbromide (1.06 g, 5.14 mmol) was added and the mixture stirred and heated at 50°C for 16h. After the mixture was concentrated under reduced pressure and the residue was treated with water to give a solid, which was collected by vacuum filtration. Next the solid was refluxed for 4h in aq. 10% NaOH (10 mL) and the resulting mixture was cooled and made acid with 1N aq. HCI. The white solid formed was collected by filtration and washed with n-hexane and Et2O, giving the derivative 3.9 as white solid (857 mg, 3.23 mmol, 75% yield).
1H-NMR (400 MHz, DMSO-de): δ 5.30 (s, 2H, CH2); 6.78 (t, 1H, J = 6.9 Hz, Ar); 7.22-7.24 (m, 1H, Ar); 7.41-7.53 (m, 2H, Ar); 8.41 (d, 2H, J = 6.9 Hz, Ar) ppm. Anal. Calcd for C13H9NO3F2: C, 58,87%; H, 3.42%; N, 5.28%; Found: C, 58,99%; H, 3.47%; N, 5.43%.

Synthesis of 1-(3,4-difluorobenzyl)-2-oxo-N-(2-oxoindolin-5-yl)-1,2-dihydropyridine-3-carboxamide (SST143).



[0067] The carboxylic derivative 3 (300 mg, 1.13 mmol) and the amine 2(168 mg, 1.13 mmol) were combined through a condensation reaction in presence of the condensing agent TBTU (363 mg, 1.13 mmol). The solvents were evaporated under reduced pressure and the crude product was purified by flash chromatography over silica gel, using 0 - 4% MeOH as a gradient in CHCl3, to obtain pure SST143 as a white solid (210 mg, 0.53 mmol, 47% yield).
mp: 285-288 °C. 1H-NMR (400 MHz, DMSO-d6): δ 3.48 (s, 2H, CH2 indole); 5.28 (s, 2H, CH2); 6.68 (dd, 1H, J= 6.8, 7.2 Hz, Ar); 6.77 (d, 1H, J = 8.4 Hz, Ar); 7.20-7.23 (m, 1H, Ar); 7.40-7.52 (m, 3H, Ar); 7.66 (s, 1H, Ar); 8.29 (dd, 1H, J = 2.2, 6.8 Hz, Ar); 8.46 (dd, 1H, J = 2.2, 6.8 Hz, Ar); 10.33 (s, 1H, NH), 11.87 (s, 1H, NH) ppm. 13C-NMR (101 MHz, DMSO-d6): δ 176.23, 161.54, 160.73, 150.35, 147.90, 143.78, 143.42, 139.86, 134.02, 132.32, 126.40, 124.90, 120.35, 119.02, 117.74, 117.25, 116.90, 109.10, 107.22, 51.45, 36.02 ppm. 19F-NMR (376 MHz; DMSO-d6): δ -138.17 (d, 1 F, J = 24 Hz); -139.76 (d, 1 F, J = 24 Hz) ppm. Anal. Calcd for C21H15F2N3O3: C, 63.80%; H, 3.82%; N 10.63%; Found: C, 63.72%; H, 3.55%; N, 10.50%.

Synthesis of (Z)-N-(3-((1H-imidazol-5-yl)methylene)-2-oxoindolin-5-yl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (JJ31)



[0068] The crude product was purified by crystallization from EtOH, affording the Z-isomer as a yellow solid (29 mg, 0.06 mmol, 34% yield).
mp: 285-288 °C. 1H-NMR (400 MHz, DMSO-d6): δ 5.31 (s, 2H, CH2); 6.70 (dd, 1H, J = 6.8, 7.2 Hz, Ar); 6.87 (d, 1H, J = 8.4 Hz, Ar); 7.22-7.25 (m, 1H, Ar); 7.42-7.62 (m, 3H, Ar); 7.68 (s, 1H, Ar); 7.94 (s, 1H, CH=); 8.01 (s, 1H, Ar); 8.03 (s, 1H, Ar); 8.32 (d, 1H, J = 7.2 Hz, Ar); 8.50 (d, 1H, J = 6.8 Hz, Ar); 11.00 (s, 1H, NH); 11.99 (s, 1H, NH) ppm. 13C-NMR (101 MHz, DMSO-d6): δ 169.05, 161.58, 160.85, 150.36, 147.91, 143.85, 143.55, 139.67, 138.75, 136.10, 134.09, 132.79, 128.13, 124.85, 123.45, 120.29, 119.87, 117.86, 117.69, 117.25, 117.08, 111.39, 109.94, 107.28, 51.53 ppm. 19F-NMR (376 MHz; DMSO-d6): - 138.13 (d, 1 F, J = 24 Hz); -139.76 (d, 1 F, J = 24 Hz) ppm. Anal. Calcd for C25H17F2N5O3: C, 63.15%; H, 4.03%; N 14.73%; Found: C, 63.34%; H, 4.17%; N, 14.89%.

Example 2:


Preparation of compounds IB35, IB36, SA16, SA23, DD21-23, DD25, DF8 and DF9



[0069] The compounds IB35, IB36, SA16, SA23, DD21-23, DD25, DF8 and DF9 were prepared by following Scheme 2

Reagents and conditionsa: I) (Boc)2O, NaOH 1 M/iPrOH 4:3, r.t., 2h; II) 5-amino-2-oxo-indole, TBTU, DIPEA, dry DMF, r.t., 16h; III) TFA, DCM, -10°C/-20°C, 3h; IV) TBTU, DIPEA, dry DMF, r.t., 16h; V) Appropriate carbaldehyde, iPrOH, DMF, piperidine, 110 °C, 4h
(r=0 and R=H IB32, IB35, IB36; r=0 and R=Phenyl SA16 and SA23; r=1 and R= H D21, D22, D23, DD25; r=2 and R=H, DF8, DF9)

[0070] The compounds of Formula (II) were synthesised by the insertion of a linker to tether the 2-oxindole nucleus and the difluoro-benzylpyridonyl core. The synthetic procedure was carried out through amide condensation by using as spacer amino acids, such as glycine, (R)-(-)-2-phenylglycine or β-alanine.

[0071] The appropriate aminoacid was protected on amine group with (Boc)2O and condensed with 5-amino-oxindole, leading to the amide derivative 5a-d. Subsequently the deprotection reaction with trifluoroacetic acid afforded the amine 6a-d as trifluoroacetic salt, which was reacted with carboxylic acid 3 to give the derivative IB32 or 7. Knovenagel reaction with the appropriate carbaldehyde, in the presence of a catalytic amount of piperidine, provided the final desired compounds IB35-36, SA16, SA23, DD21-23, DD25, DF8 and DF9. As previously observed the new compounds were obtained as Z, E or E/Z mixture isomeric form. Again the configurations were assigned by analyzing their 1H NMR spectra.

General procedure for the synthesis of N-(tert-butoxycarbonyl)aminoacid derivatives(4a-d)



[0072] To a solution of appropriate aminoacid (13.32 mmol) in 1M NaOH/iPrOH (4:3) was added BoC2O (2.9 g, 13.32 mmol). The reaction, monitored by TLC, was stirred at room temperature for 2h and then washed with Et2O, acidified to pH 3.0 with 1N HCI and finally extracted several time with AcOEt. The organic layer was dried over anhydrous Na2SO4 and evaporated under reduced pressure. The crude product 4a-d was used for the next step without further purification (1.68 g, 9.59 mmol, 72% yield).

[0073] 2-((tert-butoxycarbonyl)amino)acetic acid (4a) 1H-NMR (400 MHz, CDCl3): δ 1.45 (s, 9H, Boc); 3.90-4.08 (m, 2H, CH2); 5.07 (br s, 1H, NH) ppm. Anal. Calcd for C7H13NO4: C, 47.99%; H, 7.48%; N 8.00%; Found: C, 48.18%; H, 7.36%; N, 8.26%.

[0074] (R)-2-((tert-butoxycarbonyl)amino)-2-phenylacetic acid (4b) 1H-NMR (400 MHz, CDCl3): δ 1.21 (s, 6H, Boc); 1.43 (s, 3H, Boc); 5.12-5.51 (m, 1H); 7.29-7.44 (m, 5 H); 7.96 (br s, 1H, NH) ppm. Anal. Calcd for C13H17NO4: C, 62.14%; H, 6.82%; N 5.57%; Found: C, 62.18%; H, 7.06%; N, 5.86%.

[0075] 3-((tert-butoxycarbonyl)amino)propanoic acid (4c) 1H-NMR (400 MHz, CDCl3): δ 1.43 (br s, 9H, Boc); 2.52-2.59 (m, 2H); 3.39-3.41 (br s, 2H); 5.05-5.17 (m, 1H); Anal. Calcd for C8H15NO4: C%, 50.78%; H, 7.99; N 7.40; Found% : C, 51.02; H, 8.02; N, 7.54.

[0076] 4-((tert-butoxycarbonyl)amino)butanoic acid (4d): The crude product (921 mg, 4.53 mmol, 50% yield) was used for the next step without further purification. 1H NMR (400 MHz, CDCl3): δ 1.44 (s, 9H, CH3); 1.79-1.86 (m, 2H, CH2); 2.40 (t, 2H, J=7.2 Hz, CH2); 3.20-3.18 (m, 2H, CH2) ppm. Anal. Calcd for C9H17NO4: C, 53.19%; H, 8.43%; N, 6.89%; Found: C, 53.07%; H, 8.57%; N, 6.93%.

General procedure for the synthesis of compounds 5a-d



[0077] N-Boc derivative 4a-d (2.64 mmol) was reacted through a condensation reaction with 5-amino-indol-2-one (391mg, 2.64 mmol), in the presence of the condensing agent TBTU (848 mg, 2.64 mmol) and DIPEA (5.28 mmol, 0.92 mL) as a base.

tert-butyl (2-oxo-2-((2-oxoindolin-5-yl)amino)ethyl)carbamate (5a)



[0078] The amide was obtained after purification of the crude product by column chromatography over silica gel using CHCl3/MeOH 92:8 as the eluent (693 mg, 2.27 mmol, 86% yield). 1H-NMR (400 MHz, DMSO-d6): δ 1.39 (s, 9H, Boc); 3.46 (s, 2H, CH2 indole); 3.68 (d, 2H, J = 6.0 Hz, CH2 glycine); 6.73 (d, 1H, J = 8.2 Hz, Ar); 7.00 (t, 1H, J = 6.0 Hz, NH); 7.32 (dd, 1H, J=2.0, 8.2 Hz, Ar); 7.49 (s, 1H, Ar); 9.74 (br s, 1H, NH); 10.27 (br s, 1H, NH) ppm. Anal. Calcd for C15H19N3O4: C, 59.01%; H, 6.27%; N 13.76%; Found: C, 59.10%; H, 6.19%; N, 13.99%.

(R)-tert-butyl (2-oxo-2-((2-oxoindolin-5-yl)amino)-1-phenylethyl)- carbamate (5b)



[0079] Final compound has been purified by column chromatography over silica gel using CHCl3/MeOH 92:8 as the eluent. 1H-NMR (400 MHz, DMSO-d6): δ 1.39 (s, 9H, Boc); 3.44 (s, 2H, CH2 indole); 5.30-5.33 (m, 1H); 6.72 (d, 1H, J = 8.4 Hz, Ar); 7.26-7.36 (m, 4H, Ar); 7.44-7.48 (m, 4H, Ar); 10.09 (br s, 1H, NH); 10.29 (br s, 1H, NH) ppm. Anal. Calcd for C21H23N3O4: C, 66.13%; H, 6.08%; N 11.02%; Found: C, 66.17%; H, 6.23%; N, 11.21%.

3-((tert-butoxycarbonyl)-amino)-N-(2-oxo-2,3-dihydro-1H-indol-5-yl)propanamide(5c)



[0080] Final compound has been purified by column chromatography over silica gel using CHCl3/MeOH 92:8 as the eluent. 1H-NMR (400 MHz, DMSO-d6): δ 1.39 (s, 9H, Boc); 2.42 (t, 2H, J = 7.2 Hz); 3.16-3.22 (m, 2H); 3.45 (s, 2H); 6.71 (d, 1H, J = 8.2 Hz, Ar); 6.84-6.88 (m, 1H); 7.32(d, 1H, J= 8.2Hz); 7.50 (s, 1H, Ar); 9.78 (br s, 1H, NH); 10.28 (br s, 1H, NH) ppm. Anal. Calcd for C16H20N3O4: C, 60.37%; H, 6.33%; N 13.20%; Found: C, 60.17%; H, 6.23%; N, 13.22%.

4-((tert-butoxycarbonyl)-amino)-N-(2-oxo-2,3-dihydro-1H-indol-5-yl)butanamide (5d)



[0081] Final compound (726 mg, 1.92 mmol, 95% yield) has been purified by column chromatography over silica gel using CHCl3/MeOH (95:5) as the eluent. 1H NMR (400 MHz, DMSO-d6): δ 1.37 (s, 9H, CH3); 1.65-1.69 (m, 2H, CH2); 2.24 (t, 2H, J = 7.6 Hz, CH2); 2.92-2.97 (m, 2H, CH2); 3.44 (s, 2H, CH2); 6.71 (d, 1H, J = 8.2 Hz, Ar); 6.79 (br s, 1H, NH); 7.30 (d, 1H, J = 8.2 Hz, Ar); 7.49 (s, 1H, Ar); 9.68 (br s, 1H, NH); 10.23 (br s, 1H, NH) ppm. Anal. Calcd for C17H23N3O4: C, 61.25%; H, 6.95%; N, 12.60%; Found: C, 60.98%; H, 6.89%; N, 12.41%.

General procedure for the synthesis of compounds 6a-d



[0082] To a stirred suspension of 5a-d (2.27 mmol) in DCM (4.54 mL) cooled at -10°C/- 20°C, was added TFA (4.54 mL). The reaction was monitored by TLC and reached completion in 3h at the same temperature. Then the reaction mixture was evaporated to dryness to afford 6a-d as a trifluoroacetic salt, used for the following step without further purifications.

2-oxo-2-((2-oxoindolin-5-yl)amino)ethanaminium 2,2,2-trifluoro-acetate(6a)



[0083] 1H-NMR (400 MHz, DMSO-d6): δ 3.49 (s, 2H, CH2 indole); 3.74 (d, 2H, J = 5.6 Hz, CH2 glycine); 6.78 (d, 1H, J = 8.0 Hz, Ar); 7.33 (dd, 1H, J = 2.2, 8.2 Hz, Ar); 7.47 (s, 1H, Ar); 8.09 (br s, 3H, NH3+); 10.26 (br s, 1H, NH); 10.34 (br s, 1H, NH) ppm.

(R)-2-oxo-2-((2-oxoindolin-5-yl)amino)-1-phenylethanaminium 2,2,2-trifluoroacetate (6b)



[0084] 1H-NMR (400 MHz, DMSO-d6): δ 3.47 (s, 2H, CH2); 5.03-5.05 (m, 1H); 6.76 (d, 1H, J = 8.4 Hz, Ar); 7.29 (dd, 1H, J = 2.0, 8.4 Hz, Ar); 7.42-7.50 (m, 3H, Ar); 7.57-7.59 (m, 2H, Ar); 8.72-8.74 (m, 1H, Ar); 10.36 (br s, 1H, NH); 10.47 (br s, 1H, NH) ppm.

3-amino-N- (2-oxo-2,3-dihydro- 1H-indol-5-yl)propanamide (6c)



[0085] 1H-NMR (400 MHz, DMSO-d6): δ 2.66 (t, 2H, J= 6.8Hz); 3.06-3.11 (m, 2H); 3.49 (s, 2H, CH2 indole); 6.75 (d, 1H, J = 8.4 Hz, Ar); 7.33 (dd, 1H, J = 2.0, 8.4 Hz, Ar); 7.50 (s, 1H, Ar); 7.79 (br s, 3H, NH3+); 10.02 (br s, 1H, NH); 10.33 (br s, 1H, NH) ppm.

[0086] 4-amino-N-(2-oxo-2,3-dihydro-1H-indol-5-yl)butanamide (6d) 1H NMR (400 MHz, DMSO-d6): δ 1.82-1.85 (m, 2H, CH2); 2.38 (t, 2H, J = 6.8 Hz, CH2); 2.83-2.85 (m, 2H, CH2); 3.45 (s, 2H, CH2); 6.73 (d, 1H, J = 8.0 Hz, Ar); 7.31 (d, 1H, J= 8.0 Hz, Ar), 7.50 (s, 1H, Ar); 7.76 (br s, 3H, NH3+); 9.84 (br s, 1H, NH); 10.29 (br s, 1H, NH) ppm.

1-(3,4-difluorobenzyl)-2-oxo-N-(4-oxo-4-((2-oxoindolin-5-yl)amino)butyl)-1,2-dihydropyridine-3-carboxamide. (7)



[0087] Carboxylic acid 3 (480 mg, 1.81 mmol) was reacted through a condensation reaction with the amine salt 6d (480 mg, 1.81 mmol), in the presence of TBTU (581.16 mg, 1.81 mmol). The procedure followed is the same described for derivative SST143 in example 1. The crude product was purified by flash chromatography over silica gel, using CHCl3/MeOH (92:8) as the eluent, to obtain pure 7 as a white solid (680 mg, 1.42 mmol, 79% yield).
Mp: 199-204°C 1H NMR (400 MHz, DMSO-d6): δ 1.76-1.84 (m, 2H, CH2); 2.30 (t, 2H, J = 7.6 Hz, CH2); 3.34-3.36 (m, 2H, CH2); 3.43 (s, 2H, CH2); 5.20 (s, 2H, CH2); 6.57 (t, 1H, J = 7.2 Hz, Ar); 6.70 (d, 1H, J = 8.4 Hz, Ar); 7.16-7.19 (m, 1H, Ar); 7.30 (dd, 1H, J = 2.0, 8.4 Hz, Ar); 7.38-7.48 (m, 3H, Ar); 8.21 (dd, 1H, J = 2.2, 7.2 Hz, Ar); 8.34 (dd, 1H, J = 2.2, 7.2 Hz, Ar); 9.66 (br t, 1H, J =5.8 NH); 9.74 (br s, 1H, NH); 10.25 (br s, 1H, NH) ppm. 13C-NMR (101 MHz, DMSO-d6): δ 176.23; 170.15; 162.98; 161.23; 150.31; 147.87; 143.40; 142.92; 139.06; 134.21; 133.38; 125.90; 124.85; 120.49; 118.42; 117.70; 117.20; 116.46; 108.73; 106.60; 51.26; 38.29; 36.01; 33.85; 25.41 ppm. 19F-NMR (376 MHz, DMSO-d6): δ -138.23 (d, 1 F, J = 22 Hz); - 139.82 (d, 1 F, J = 24 Hz) ppm. Anal. Calcd for C25H22N4O4F2: C, 62.50%; H, 4.62%; N, 11.66%; Found: C, 62.32%; H, 4.79%; N, 11.81%.

Synthesis of 1-(3,4-difluorobenzyl)-2-oxo-N-(2-oxo-2-((2-oxoindolin-5-yl)amino)ethyl)-1,2-dihydropyridine-3-carboxamide (IB32).



[0088] Starting from carboxylic acid 3 (154 mg, 0.58 mmol) and the 2-oxo-2-((2-oxoindolin-5-yl)amino)ethanaminium 2,2,2-trifluoro-acetate (0.58 mmol), the amide derivative was synthetized, using TBTU (187 mg, 0.58 mmol) as condensing agent. The procedure followed is the same described for derivative SST143 in above example 1.

[0089] The crude product was purified by column chromatography over silica gel using CHCl3/MeOH 92:8 as the eluent to obtain the product as a white solid (63 mg, 0.14 mmol, 25% yield).
mp: 257-262°C. 1H-NMR (400 MHz, DMSO-d6): δ 3.45 (s, 2H, CH2 indole); 4.13 (d, 2H, J = 5.2 Hz, CH2 glycine); 5.23 (s, 2H, CH2); 6.58 (t, 1H, J = 6.9 Hz, Ar); 6.74 (d, 1H, J = 8.4 Hz, Ar); 7.19-7.22 (m, 1H, Ar); 7.33 (dd, 1H, J= 2.0, 8.4 Hz, Ar); 7.40-7.50 (m, 3H, Ar); 8.25 (dd, 1H, J = 2.1, 6.9 Hz, Ar); 8.35 (dd, 1H, J = 2.1, 6.9 Hz, Ar); 9.94 (br s, 1H, NH); 9.99 (t, 1H, J = 5.2 Hz, NH); 10.28 (br s, 1H, NH) ppm. 13C-NMR (101 MHz, DMSO-d6): δ 176.17, 166.69, 163.04, 161.09, 150.22, 147.83, 143.48, 143.19, 139.33, 134.18, 132.82, 126.05, 124.89, 120.20, 118.48, 117.65, 117.23, 116.44, 108.81, 106.45, 51.34, 43.05, 35.97 ppm. 19F-NMR (376 MHz; DMSO-d6): δ -138.27 (d, 1 F, J = 24 Hz); -139.80 (d, 1F, J = 24 Hz) ppm. Anal. Calcd for C23H18N4O4F2: C, 61.06%; H, 4.01%; N 12.38%; Found: C, 61.22%; H, 4.00%; N, 12.51%.

General procedure to synthesize compounds IB35, IB36, SA16, SA23, DD21-23, DD25, DF8, DF9



[0090] To a solution of 2-oxo-indole derivative (0.12 mmol) dissolved in iPrOH/DMF or absolute EtOH (5 mL), was added the appropriate carbaldehyde (0.12 mmol) and a catalytic amount of piperidine. The resulting solution was stirred and heated to reach 110°C for 4h, then the solution was evaporated to dryness. The residual material was purified by crystallization.

(E/Z)-1-(3,4-difluorobenzyl)-2-oxo-N-(2-oxo-2-((2-oxo-3-(thiophe-2-ylmethylene)indolin-5-yl)amino)ethyl)-1,2-dihydropyridine-3-carboxamide (IB36)



[0091] The residual material was purified by crystallization from iPrOH, affording the final product as an orange solid consisting in a 1:2 E/Z isomeric mixture (35 mg, 0.06 mmol, 53% yield). mp: 223-227°C. 1H-NMR (400 MHz, DMSO-d6): δ 4.17 (d, 2H, J = 4.8 Hz, CH2 glycine); 5.24 (s, 2H, CH2); 6.59 (t, 1H, J = 7.0 Hz, Ar); 6.80 (d, 0.66H, J = 8.4 Hz, Ar); 6.85 (d, 0.33H, J = 8.4 Hz, Ar); 7.17-7.23 (m, 2H, Ar); 7.31-7.33 (m, 0.33H, Ar); 7.40-7.50 (m, 2.66H, Ar); 7.78 (s, 0.33H, E-isomer, Ar); 7.82 (d, 0.33H, J = 3.6 Hz, Ar, E-isomer); 7.89 (d, 0.66H, J = 4.8 Hz, Ar, Z-isomer); 7.98-8.00 (m, 1.32H, Ar, Z-isomer); 8.03-8.05 (m, 1H, Ar, E+Z-isomers); 8.26-8.28 (m, 1H, Ar, E+Z-isomers); 8.36-8.39 (m, 1H, Ar, E+Z-isomers); 8.58 (s, 0.33H, C4, J = 1.6 Hz Ar, E-isomer); 9.99-10.05 (m, 1.66H, NH); 10.11 (br s, 0.33H, NH); 10.55 (br s, 1H, NH) ppm. 13C-NMR (DMSO-d6): δ 169.27, 167.41, 166.95, 166.89 163.12, 161.15, 150.41, 147.90,138.46, 138.16, 137.23, 137.12, 136.58, 136.03, , 134.57, 134.26, 132.88, 132.64, 132.19, 128.73, 128.26, 127.40, 124.93, 124.31, 123.54, 121.69, 121.06, 120.75, 120.29, 117.73, 117.28, 115.08, 111.59, 109.65, 106.54, 51.45, 43.08 ppm. 19F-NMR (376 MHz; DMSO-d6): δ -138.24 (d, 1F, J = 24 Hz); -139.76 (d, 0.33F, J = 24 Hz), -139.79 (d, 0.66F, J = 24 Hz) ppm. Anal. Calcd for C28H20N4O4F2S: C, 61.53%; H, 3.69%; N 10.25%; Found: C, 61.62%; H, 3.63%; N, 10.39%.

(Z)-N-(2-((3-((1H-imidazol-5-yl)methylene)-2-oxoindolin-5-yl)amino)-2-oxoethyl)-1-(3,4-difluorobenzyl)-2-oxo- 1,2-dihydro pyridine-3-carboxamide (IB35)



[0092] The residual material was purified by crystallization from iPrOH, affording the Z-isomer as a yellow solid (32 mg, 0.06 mmol, 52% yield). mp: 230-235°C. 1H-NMR (400 MHz, DMSO-d6): δ 4.17 (d, 2H, J = 4.4 Hz, CH2glycine); 5.24 (s, 2H, CH2); 6.60 (t, 1H, J = 6.9 Hz, Ar); 6.85 (d, 1H, J = 8.8 Hz, Ar); 7.19-7.21 (m, 2H, Ar); 7.43-7.50 (m, 3H, Ar); 7.71 (s, 1H, Ar); 7.75 (s, 1H, Ar); 8.01 (s, 1H, Ar); 8.05 (s, 1H, Ar); 8.27 (dd, 1H, J = 2.0, 6.9 Hz, Ar); 8.37 (d, 1H, J = 2.0, 6.9 Hz, Ar); 10.61 (br s, 2H, NH); 10.95 (br s, 1H, NH) ppm. 13C-NMR (101 MHz, DMSO-d6): δ 169.05, 166.93, 163.12, 161.16, 150.41, 147.90, 143.57, 143.31, 139.62, 138.85, 135.79, 134.32, 133.20, 128.07, 124.93, 124.47, 122.90, 120.25, 120.10, 119.67, 117.73, 117.23, 111.17, 109.86, 106.52, 51.45, 43.14 ppm. 19F-NMR (376 MHz; DMSO-d6): δ -138.25 (d, 1F, J = 24 Hz); -139.80 (d, 1F, J = 24 Hz) ppm. Anal. Calcd for C27H20N6O4F2: C, 61.13%; H, 3.80%; N 15.84%; Found: C, 61.15%; H, 4.03%; N, 15.89%.

(Z)-(R)-N-(2-((3-((1H-imidazol-5-yl)methylene)-2-oxoindolin-5-yl)amino)-2-oxo-1-phenylethyl)- 1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (SA16)



[0093] The residual material was purified by crystallization from EtOH, affording the Z-isomer as a yellow solid (41 mg, 0.07mmol, 57% yield). mp: 248-255°C. 1H-NMR (400 MHz, DMSO-d6): δ 5.20-5.31 (m, 2H, CH2); 5.81 (d, 1H, J = 7.2 Hz, CH2); 6.60 (t, 1H, J = 6.8 Hz, Ar); 6.83 (d, 1H, J = 8.0 Hz, Ar); 7.19-7.21 (m, 2H, Ar); 7.29-7.52 (m, 8H, Ar); 7.71 (s, 1H, Ar); 7.78 (s, 1H, Ar); 8.01 (s, 1H, Ar); 8.04 (s, 1H, Ar); 8.27 (dd, 1H, J = 2.0, 6.8 Hz, Ar); 8.35 (dd, 1H, J = 2.0, 6.8 Hz, Ar); 10.46 (br s, 1H, NH); 10.72 (d, 1H, J = 7.2 Hz, NH); 10.97 (br s, 1H, NH) ppm. 13C-NMR (101 MHz, DMSO-d6): δ 169.03, 167.95, 162.32, 161.30, 150.35, 147.91, 143.82, 143.57, 139.68, 138.95, 138.72, 136.04, 134.24, 132.92, 128.70, 128.07, 127.89, 126.83, 124.87, 124.51, 123.16, 119.90, 119.77, 117.79, 117.15, 111.16, 109.88, 106.68, 57.06, 51.36 ppm. Anal. Calcd for C33H24N6O4F2: C, 65.34%; H, 3.99%; N 13.85%; Found: C, 65.25%; H, 4.03%; N, 13.79%.

(Z)-(R)-N-(2-((3-((1H-imidazol-2-yl)methylene)-2-oxoindolin-5-yl)amino)-2-oxo-1-phenylethyl)- 1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (SA23)



[0094] The residual material was purified by crystallization from EtOH, affording the yellow solid as the Z-isomer, which slowly interconverts in 2:1 E/Z mixture (45 mg, 0.07 mmol, 62% yield). mp: 304-307°C. 1H-NMR (400 MHz, DMSO-d6) [t=0]: δ 5.20-5.30 (m, 2H, CH2); 5.81 (d, 1H, J= 7.2 Hz, CH2); 6.60 (t, 1H, J = 7.0 Hz, Ar); 6.86 (d, 1H, J = 8.4 Hz, Ar); 7.17-7.20 (m, 1H, Ar); 7.21-7.56 (m, 11H, Ar); 7.58 (s, 1H, CH=); 7.86 (d, 1H, J = 2.0 Hz, C4, Ar); 8.26 (dd, J = 2.0, 7.0 Hz, 1H, Ar); 8.36 (dd, J = 2.0, 7.0 Hz, 1H, Ar); 10.45 (br s, 1H, NH); 10.68 (d, 1H, J = 7.2 Hz, NH); 11.11 (br s, 1H, NH) ppm. 19F-NMR (376 MHz; DMSO-d6) [t=0]: δ - 138.14 (d, 1 F, J = 24 Hz); -139.76 (d, 1 F, J = 24 Hz) ppm. 13C-NMR (101 MHz, DMSO-d6) [t=12h]: δ 169.50 (Z-isomer), 168.89 (E-isomer), 168.01, 162.31, 162.25, 161.26, 150.46, 147.44, 143.78 (E-isomer), 143.50 (Z-isomer), 143.35 (E-isomer), 142.89 (Z-isomer), 138.92 (Z-isomer), 138.86 (Z-isomer), 138.56 (E-isomer), 136.23 (E-isomer), 134.16, 133.09, 132.62, 132.11, 128.68 (E-isomer), 128.60 (Z-isomer), 127.87 (E-isomer), 127.77 (Z-isomer), 126.85, 124.85, 124.31, 123.95, 123.42, 122.36, 121.90, 120.91 (Z-isomer), 120.79 (E-isomer), 119.93 (Z-isomer), 119.86 (E-isomer), 117.74, 117.16, 111.74, 110.06, 108.85, 106.65, 57.06, 51.28 ppm. 19F-NMR (376 MHz; DMSO-d6) [t=24h]: δ -138.14 (d, 0.33F, J= 24 Hz, Z-isomer); -138.16 (d, 0.66F, J = 24 Hz, E-isomer); -139.76 (d, 0.33F, J = 24 Hz, Z-isomer); -139.79 (d, 0.66F, J = 24 Hz, E-isomer) ppm. Anal. Calcd for C33H24N6O4F2: C, 65.34%; H, 3.99%; N 13.85%; Found: C, 65.25%; H, 4.03%; N, 13.79%.

(E/Z)-1-(3,4-difluorobenzyl)-2-oxo-N-(3-oxo-3-((2-oxo-3-(thiophen-2-ylmethylene)indolin-5-yl)amino)propyl)-1,2-dihydropyridine-3-carboxamide (DD22).



[0095] The residual material was purified by crystallization from iPrOH. 1H-NMR (400 MHz, DMSO-d6): δ 2.57-2.59 (m, 2H, CH2); 3.57-3.61 (m, 2H, CH2); 5.22 (s, 2H, CH2 benzylic); 6.57 (t, 1H, J = 6.8Hz, Ar); 6.78 (d, 0.75H, J = 8.4 Hz, Ar); 6.81 (d, 0.25H, J = 8.4 Hz, Ar); 7.15-7.22 (m, 3H, Ar); 7.31-7.44 (m, 2 H, Ar); 7.76 (s, 0.25H, E-isomer, Ar); 7.89 (d, 0.90H, J = 3.2 Hz, Ar, Z-isomer); 7.96-8.00 (m, 3H, Ar, E+Z-isomer); 8.19-8.21 (m, 1H, Ar, E+Z-isomer); 8.35-8.38 (m, 1H, Ar, E+Z-isomer); 8.58 (s, 0.11H, C4, J = 1.6 Hz Ar, E-isomer); 9.79 (br s, 1H, NH); 9.87 (m, 0.80H, NH); 9.95 (m, 0.20H, NH); 10.52 (br s, 0.35H, NH); 10.55 (br s, 1H, NH) ppm.

(ZIE)-N-(3-((3-((1 H-imidazol-2-yl)methylene)-2-oxoindolin-5-yl)amino)-3-oxopropyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide(mix 88:12=Z:E) (DD25)



[0096] 1H-NMR (400 MHz, DMSO-d6): δ 2.58 (t, 2H, J = 6.4Hz, CH2); 3.59 (q, 2H, J = 6.4 Hz, CH2); 4.17 (d, 2H, J=4.4 Hz, CH2); 5.20 (s, 2H, CH2); 6.57 (t, 1H, J=6.8 Hz, Ar); 6.82 (d, 1H, J=8.4 Hz, Ar); 7.12-7.14 (m, 1H,Ar); 7.33-7.43 (m, 4H, Ar); 7.52 (s, 1H, Ar); 7.56 (s, 1H, Ar); 7.92 (s, 1H, Ar); 8.19 (dd, 1H, J =2.0, 6.8 Hz, Ar); 8.35 (dd, 1H, J =2.0, 6.8 Hz, Ar); 9.81 (br s, 1H, NH); 9.91 (s, 1H, NH); 11.08 (br s, 1H, NH) ppm.

(Z)-N-(3-((3-((1H-imidazol-5-yl)methylene)-2-oxoindolin-5-yl)amino)-3-oxopropyl)- 1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (DD21)



[0097] 1H-NMR (400 MHz, DMSO-d6): δ 2.59 (br m, 2H, CH2); 3.57-3.61 (m, 2H, CH2); 5.19 (s, 2H, CH2); 6.57 (t, 1H, J=6.8 Hz, Ar); 6.82 (d, 1H, J=8.0 Hz, Ar); 7.14-7.21 (m, 2H,Ar); 7.33-7.45 (m, 2H, Ar); 7.71 (s, 1H, Ar); 8.01 (s, 1H, Ar); 8.19 (d, 1H, J =6.0 Hz, Ar); 8.36 (d, 1H, J =6.0 Hz, Ar); 9.80 (br s, 1H, NH); 9.90 (br s, 1H, NH); 10.93 (br s, 1H, NH) ppm.

(Z)-1-(3,4-difluorobenzyl)-N-(3-((3-(4-fluorobenzylidene)-2-oxoindolin-5-yl)amino)-3-oxopropyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (DD23)



[0098] 1H-NMR (400 MHz, DMSO-d6): δ 2.50-2.53 (m, 2H, CH2); 3.53-3.55 (m, 2H,CH2); 5.18 (s, 2H, CH2 benzylic); 6.56 (t, 1H, J = 7.2 Hz, Ar); 6.80 (d, 1H, J = 8.4 Hz, Ar); 7.10-7.16 (m, 1H, Ar); 7.32-7.44 (m, 5H, Ar); 7.58 (s, 1H, CH=); 7.76-7.80 (m, 2H, Ar); 7.98 (s, 1H, C4 Ar); 8.20 (d, 1H, J = 6.4 Hz, Ar); 8.34 (d, 1H, J = 6.4 Hz, Ar); 9.78-9.82 (m, 2H, NH); 10.53 (br s, 1H, NH) ppm.

[0099] (Z)-N-(4-((3-((1H-imidazol-5-yl)methylene)-2-oxoindolin-5-yl)amino)-4-oxobutyl)-5-(3,4-difluorobenzyl)-6-oxocyclohexa-1,3-diene-1-carboxamide (DF8). To a solution of 2-oxo-indole derivative 7 (70 mg, 0.15 mmol) dissolved in iPrOH/DMF, was added the 4-imidazole-carbaldehyde (14 mg, 0.15 mmol) and a catalytic amount of piperidine. The procedure followed is the same described for derivative IB35. The residual material was purified by crystallization from iPrOH, affording the Z isomer as an orange solid (44 mg, 0.08 mmol, 66% yield). Mp: 240-244° C. 1H NMR (400 MHz, DMSO-d6): δ: 1.80-1.85 (m, 2H, CH2); 2.34 (t, 2H, J = 7.2 Hz, CH2); 3.35-3.39 (m, 2H, CH2); 5.19 (s, 2H, CH2); 6.57 (t, 1H, J = 7.0 Hz, Ar); 6.80 (d, 1H, J= 8.4 Hz, Ar); 7.18-7.21 (m, 2H, Ar); 7.38-7.46 (m, 2H, Ar); 7.65-7.75 (m, 2H, Ar); 7.95-8.05 (m, 2H, Ar); 8.20 (dd, 1H, J = 1.8, 7.0 Hz, Ar); 8.35 (dd, 1H, J = 1.8, 7.0 Hz, Ar); 9.68 (br t, 1H, J = 5.6 Hz, NH); 9.84 (br s, 1H, NH); 10.89 (br s, 1H, NH) ppm. 13C-NMR (101 MHz, DMSO-d6): δ 170.33; 169.04; 162.99; 161.24; 150.05; 147.87; 143.41; 142.91; 139.52; 138.73; 134.20; 133.68; 124.85; 124.30; 122.70; 120.50; 120.20; 119.77; 117.70; 117.20; 111.22; 109.70; 106.60; 51.27; 38.31; 33.79; 25.38 ppm. 19F-NMR (376 MHz, DMSO-d6): δ: -138.22 (d, 1 F, J = 24 Hz); - 139.81 (d, 1 F, J = 24 Hz) ppm. Anal. Calcd for C29H24N6O4F2: C, 62.36%; H, 4.33%; N, 15.05%; Found: C, 62.66%; H, 4.21%; N, 15.39%.

[0100] (E/Z)- 1-(3,4-difluorobenzyl)-2-oxo-N-(4-oxo-4-((2-oxo-3-(thiophen-2-ylmethylene)indolin-5-yl)amino)butyl)-1,2-dihydropyridine-3-carboxamide (DF9). To a solution of 2-oxo-indole derivative 7 (70 mg, 0.15 mmol) dissolved in iPrOH/DMF, was added the 2-thiophenecarbaldehyde (17 mg, 0.15 mmol) and a catalytic amount of piperidine. The procedure followed is the same described for derivative IB35. The residual material was purified by crystallization from iPrOH affording the final product as an orange solid consisting in a 40:60 E/Z isomeric mixture (52 mg, 0.09 mmol, 76% yield).. Mp: 189-194°C. 1H NMR (400 MHz, DMSO- d6): δ 1.80-1.87 (m, 2H, CH2); 2.32-2.36 (m, 2H, CH2); 3.35-3.39 (m, 2H, CH2); 5.19 (m, 2H, CH2); 6.54-6.59 (m, 1H, Ar); 6.77 (d, 0.60 H, J = 8.0 Hz, Ar, Z isomer); 6.81 (d, 0.40 H, J = 8.4 Hz, Ar, E isomer); 7.18-7.23 (m, 2.20 H, Ar); 7.31-7.32 (m, 0.40 H, Ar, E isomer); 7.40-7.47 (m, 2.40 H, Ar); 7.76 (s, 0.40 H, Ar, E isomer); 7.81 -7.88 (m, 1H, Ar, E/Z isomer); 7.96-7.99 (m, 1.60 H, Ar), 8.03 (m, 0.60H, Ar, Z isomer); 8.20-8.22 (m, 1H, Ar); 8.33-8.37 (m, 1H, Ar); 8.61 (m, 0.40H, Ar, E isomer); 9.67-9.69 (br m, 1H, NH); 9.82 (br s, 0.60H, NH, Zisomer); 9.90 (br s, 0.40H, NH, E isomer); 10.51 (br s, 1H, NH) ppm. 13C-NMR (101 MHz, DMSO-d6): δ 170.32 (Z isomer); 169.31 (E isomer); 167.43; 163.02; 161.26; 150.34; 148.09; 143.45 (Z isomer); 142.97 (E isomer); 138.19 (E isomer); 138.04 (Z isomer); 137.23 (Z isomer); 137.18 (E isomer); 136.39 (Z isomer); 135.89 (E isomer); 134.48; 134.23; 133.39 (E isomer); 133.14 (Z isomer); 132.17; 128.70 (Z isomer); 128.08 (E isomer); 127.41 (Z isomer); 127.19 (E isomer); 124.88; 124.17 (Z isomer); 123.63 (E isomer); 121.81; 120.95; 120.65; 120.50; 120.44; 117.74; 117.23; 115.14; 111.65; 109.68 (E isomer); 109.34 (Z isomer); 106.50; 51.31; 38.34; 33.96 (E isomer); 33.77 (Z isomer); 25.42 ppm. 19F-NMR (376 MHz, DMSO- d6): δ: - 139.22 (d, 1F, J = 24 Hz) ; -139.81 (d, 1F, J = 24 Hz) ppm. Anal. Calcd for C30H24N4O4F2S: C, 62.71%; H, 4.21%; N, 9.75%; Found: C, 63.89%; H, 4.01%; N, 9.55%.

Preparation of compounds DD40 and DD41



[0101] The compounds DD40 and DD41 were prepared by following Scheme 3

Reagents and Conditions: I. SOCl2, 82°C, 12h; II. Pyridine, 3h; III. H2, Pd/C, EtOH; IV. TBTU, DIPEA, dry DMF, r.t., 16h; V. Carboxyaldehyde, Piperidine, EtOH, reflux 110°C, 4h.

[0102] 3-nitrobenzoyl chloride. 3-nitrobenzoic acid (600 mg, 3.59 mmol) and thionyl chloride (0.26 mL, 3.59 mmol) were reacted under N2 atmosphere at 82°C for 16 h. Once TLC verified the disappearance of the precursor, the solution was evaporated to dryness and the crude product was immediately/directly used for the next step without further purification.

[0103] 3-nitro-N-(2-oxoindolin-5-yl)benzamide (4e) To a mixture of nitrobenzoylchloride (3.59 mmol) in pyridine was added the 5-amino-2-oxindole (379 mg, 2.56 mmol). Mixture was stirred at room temperature for 3h and poured into ice water. The precipitate was filtered, washed with water and dried in vacuum to give final product as white powder (544.1 mg, 1.83 mmol, 71% yield). 1H-NMR (400 MHz, DMSO-d6): δ 3.51 (s, 2H, CH2); 6.81 (d, 1H, J = 8.4 Hz, Ar); 7.52 (d, 1H, J = 8.4 Hz, Ar); 7.66 (s, 1H, Ar); 7.83 (t, 1H, J = 8.0 Hz, Ar); 8.37-8.43 (m, 2H, Ar); 8.77 (s, 1H, Ar); 10.35 (br s, 1H, NH); 10.45 (br s, 1H, NH) ppm. Anal. Calcd for C15H11N3O4: C, 60.61%; H, 3.73%; N, 14.14%; Found: C, 60.78%; H, 3.86%; N, 14.05%.

[0104] 3-((2-oxoindolin-5-yl)carbamoyl)benzenaminium chloride (5e). Derivative 4e (544 mg, 1.83 mmol) dissolved in absolute EtOH (70 mL) was hydrogenated in the presence of 10% Pd-C for 4h at rt. Then the catalyst was filtered off through Celite, the Celite rinsed with additional EtOH and the solution was evaporated, to give 5e as a brown solid. Crude product was transformed in the correspondent hydrochloridric salt (171.5 mg, 0.57 mmol, 31% yield). 1H-NMR (400 MHz, CD3OD): δ 3.55 (s, 2H, CH2); 6.90 (d, 1H, J = 8.4 Hz, Ar); 7.49 (dd, 1H, J = 1.8, 8.4 Hz, Ar); 7.59-7.62 (m, 2H, Ar); 7.70 (t, 1H, J = 8.0 Hz, Ar); 7.95 (d, 1H, J = 1.8, Ar); 8.05 (d, 1H, J = 8.0 Hz, Ar) ppm. Anal. Calcd for C15H14N3O2Cl: C, 59.51%; H, 4.33%; N, 13.88%; Found: C, 59.78%; H, 4.47%; N, 13.90%. 1 -(3,4-difluorobenzyl)-2-oxo-N-(3-((2-oxoindolin-5-yl)carbamoyl)phenyl)-1,2-dihydropyridine-3-carboxamide (8). Carboxylic acid 3 (175 mg, 0.66 mmol) was reacted with amine derivative 5e (200 mg, 0.66 mmol) in dry DMF (4 mL). Reaction was conducted in presence of TBTU (212 mg, 0.66 mmol) and DIPEA (4 mL) as previously reported for compound SST143. Then the organic solvent was evaporated under vacuum and the crude product was purified by flash chromatography over silica gel, using CHCl3/MeOH (97:3) as the eluent, yielding pure 8 as a white solid (80 mg, 0.16 mmol, 24% yield). 1H-NMR (400 MHz, DMSO-d6): δ 3.50 (s, 2H, CH2); 5.31 (s, 2H, CH2); 6.71 (t, 1H, J = 7.0 Hz, Ar); 6.79 (d, 1H, J = 8.4 Hz, Ar); 7.22-7.24 (m, 1H, Ar); 7.41-7.52 (m, 4H); 7.66-7.68 (m, 2H, Ar); 8.00 (d, 1H, J = 8.4 Hz, Ar); 8.13 (s, 1H, Ar); 8.33 (dd, 1H, J = 2.0, 7.0 Hz, Ar); 8.51 (dd, 1H, J = 2.0, 7.0 Hz, Ar); 10.15 (br s, 1H, NH); 10.32 (br s, 1H, NH); 12.14 (br s, 1H, NH) ppm. 13C-NMR (101 MHz, DMSO-d6): δ 176.30, 164.75, 161.60, 161.45, 150.37, 147.92, 144.29, 143.91, 139.77, 138.28, 135.92, 134.02, 133.03, 129.07, 125.90, 124.84, 122.94, 122.48, 120.01, 118.82, 117.83, 117.67, 117.27, 117.09, 108.74, 107.34, 51.52, 36.03 ppm. 19F-NMR (376 MHz, DMSO-d6): δ -138.12 (d, 1F, J = 24 Hz, Ar); -139.73 (d, 1F, J = 24 Hz, Ar) ppm. Anal. Calcd for C28H20N4O4F2: C, 65.37 %; H, 3.92%; N, 10.89%; Found: C, 65.69%; H, 3.79%; N, 10.93%.

[0105] (Z)-N-(3-((3-((1H-imidazol-5-yl)methylene)-2-oxoindolin-5-yl)carbamoyl)phenyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (DD40). To a solution of derivative 8 (40 mg, 0.08 mmol) in iPrOH/DMF was added the 4-imidazolecarbaldehyde (8 mg, 0.08 mmol) and a catalytic amount of piperidine. The procedure followed is the same described for derivative IB35. The residual material was purified by crystallization from iPrOH affording the yellow solid as the Z isomer (15 mg, 0.03 mmol, 37% yield). M.p.: 326-330°C; 1H-NMR (400 MHz, DMSO-d6): δ 5.31 (s, 2H, CH2); 6.71 (t, 1H, J = 6.8 Hz, Ar); 6.89 (d, 1H, J = 8.4 Hz, Ar); 7.22-7.24 (m, 1H, Ar); 7.41-7.54 (m, 4H, Ar); 7.71 (d, 1H, J = 8.0, Ar); 7.75-7.77 (m, 2H, Ar); 8.01-8.03 (m, 2H, Ar); 8.10 (s, 1H, Ar); 8.18 (s, 1H, Ar); 8.33 (dd, 1H, J = 2.0, 6.8 Hz, Ar); 8.52 (dd, 1H, J = 2.0, 6.8 Hz, Ar); 10.25 (br s, 1H, NH); 12.16 (br s, 1H, NH) ppm. 13C-NMR (101 MHz, DMSO-d6): δ 164.84, 161.60, 161.46, 150.36, 147.85, 144.29, 143.91, 138.30, 136.21, 135.78, 134.02, 133.24, 129.11, 128.07, 124.81, 124.35, 122.94, 122.55, 121.36, 120.02, 118.82, 117.75, 117.16, 112.80, 109.65, 107.34, 51.52 ppm. 19F-NMR (376 MHz, DMSO-d6): δ -138.12 (d, 1F, J = 24 Hz, Ar); -139.73 (d, 1F, J = 24 Hz, Ar) ppm. Anal. Calcd for C32H22N6O4F2: C, 64.86 %; H, 3.74%; N, 14.18%; Found: C, 65.08%; H, 3.77%; N, 14.39%.

[0106] (E/Z)-1-(3,4-difluorobenzyl)-2-oxo-N-(3-((2-oxo-3-(thiophen-2-ylmethylene)indolin-5-yl)carbamoyl)phenyl)-1,2-dihydropyridine-3-carboxamide (DD41). To a solution of 2-oxo-indole derivative 8 (40 mg, 0.08 mmol) dissolved in iPrOH/DMF, was added the 2-thiophenecarbaldehyde (9 mg, 0.08 mmol) and a catalytic amount of piperidine. The procedure followed is the same described for derivative IB35. The residual material was purified by crystallization from iPrOH, affording the final product (12 mg, 0.02 mmol, 25% yield) as an orange solid consisting in a mixture of E/Z isomers (1:4). M.p.: 295-298°C; 1H-NMR (400 MHz, DMSO-d6): δ 5.32 (s, 2H, CH2); 6.71-6.73 (m, 1H, Ar); 6.86-6.88 (m, 1H, Ar); 7.23-7.34 (m, 2H, Ar); 7.44-7.52 (m, 3.75H, Ar); 7.62-8.20 (m, 7H, Ar); 8.34 (s, 1H, Ar); 8.53 (s, 1H, Ar); 8.78 (s, 0.25H, Ar, E isomer); 10.25-10.33 (br m, 1H, NH); 10.60 (br s, 1H, NH); 12.17 (br s, 1H, NH) ppm. 13C-NMR (101 MHz, DMSO-d6): δ 169.35 (E isomer), 167.45 (Z isomer), 164.97 (E isomer), 164.80 (Z isomer), 161.62, 161.47, 150.37, 147.93, 144.30, 143.92, 138.86 (E isomer), 138.32 (Z isomer), 137.96 (E isomer), 137.25 (Z isomer), 137.01 (E isomer), 135.91, 134.48, 134.01, 132.94 (E isomer), 132.70 (Z isomer), 132.25 (E isomer), 129.12 (Z isomer), 128.69 (Z isomer), 128.20 (E isomer), 127.43 (Z isomer), 124.86, 124.22, 123.59 (E isomer), 123.02 (E isomer), 122.93 (Z isomer), 122.66 (E isomer), 122.55 (Z isomer), 122.04 (Z isomer), 121.74 (Z isomer), 120.64 (E isomer), 120.04 (Z isomer), 118.92 (E isomer), 118.83 (Z isomer), 117.78, 117.18, 116.57 (E isomer), 113.26 (Z isomer), 109.68 (E isomer), 109.27 (Z isomer), 106.50, 51.54 ppm. 19F-NMR (376 MHz, DMSO-d6): δ -138.12 (d, 1F, J = 24 Hz, Ar); -139.73 (d, 1F, J = 24 Hz, Ar) ppm. Anal. Calcd for C33H22N4O4F2S: C, 65.12 %; H, 3.64%; N, 9.21%; Found: C, 65.38%; H, 3.69%; N, 9.28%.

Evaluation of the compounds of Formulas (I) and (II)



[0107] The activity of the inhibitor compounds can be assayed utilizing methods known in the art and/or methods presented therein.

[0108] The compounds of Formula (I) and (II) were tested in the biological test named Kinase-specific Z'-LYTE® assay (Invitrogen Corporation, Life Technologies). The compounds synthetized were hence subjected to FRET-based Z'-Lyte assay against PDK1 Direct kinase to evaluate the kinase inhibitory activities (Invitrogen).

[0109] Data indicate that the compounds JJ31, IB32, IB35, SA23, SA16, DD22, DD21, DD40, DF8 and DF9 displayed the best effects on PDK1 (>50% inhibition versus PDK1 at 10µM). The IC50 values and percentage of Inhibition are reported in the following table.
CompoundStructureMWPDK1(%)inhibition at 10 µM or IC50 (nM)
JJ31

473.43 512nM
IB32

452.13 6680nM
IB36

546.12 19%
IB35

530.15 112nM
SA16

606.58 416nM
SA23

606.58 1520nM
DD22

560.57 1340nM
DD21

544.51 103nM
DD23

572.53 15%
DD25

544.515 47%
DD40

592.56 245nM
DD41

608.62 26%
DF8

558.55 245nM
DF9

574.60 5880nM


[0110] Compound IB35 which showed an optimal inhibition of PDK1 was also tested for the selectivity by comparing its ability in inhibiting other kinases in the Akt pathway. The results are reported below
IB35 kinases profiling at 100nM
Compound IB35 Conc (nM)ATPKinaseTechnology% Inhibition 1% Inhibition 2% Inhibition Avg
100 Km app CDK7/cyclin H/MNAT1 Adapta 2 -1 1
100 Km app CDK9/cyclin T1 Adapta 7 5 6
100 Km app CHUK (IKK alpha) Adapta -2 7 3
100 Km app PI4KB (PI4K beta) Adapta -3 12 4
100 Km app PIK3CA/PIK3R1 (p110 alpha/p85 alpha) Adapta 16 24 20
100 Km app PIK3CD/PIK3R1 (p110 delta/p85 alpha) Adapta 13 21 17
100 Km app PIK3CG (p110 gamma) Adapta 6 -1 2
100 Km app ABL1 ZLYTE 17 12 14
100 Km app AKT1 (PKB alpha) ZLYTE -6 -9 -8
100 Km app AKT2 (PKB beta) ZLYTE 0 -9 -4
100 Km app AKT3 (PKB gamma) ZLYTE 3 1 2
100 Km app AMPK A1/B1/G1 ZLYTE 8 7 7
100 Km app AMPK A2/B1/G1 ZLYTE 10 11 10
100 Km app AURKA (Aurora A) ZLYTE 37 38 38
100 100 BRAF ZLYTE 16 17 17
100 Km app BTK ZLYTE -4 -2 -3
100 Km app CAMK2A (CaMKII alpha) ZLYTE -1 2 0
100 Km app CDC42 BPA (MRCKA) ZLYTE -1 -6 -3
100 Km app CDK1/cyclin B ZLYTE 10 3 6
100 Km app CDK2/cyclin A ZLYTE -1 8 4
100 Km app CDK5/p25 ZLYTE -7 -10 -8
100 Km app CDK5/p35 ZLYTE -2 6 2
100 Km app CHEK1 (CHK1) ZLYTE 10 2 6
100 Km app CHEK2 (CHK2) ZLYTE 1 8 4
100 Km app CLK1 ZLYTE 4 -7 -2
100 Km app CSNK1A1 (CK1 alpha 1) ZLYTE -3 -2 -2
100 Km app CSNK1G1 (CK1 gamma 1) ZLYTE 3 2 3
100 Km app CSNK2A2 (CK2 alpha 2) ZLYTE 4 3 3
100 Km app FRAP1 (mTOR) ZLYTE -10 -18 -14
100 Km app GRK5 ZLYTE -7 0 -4
100 Km app GSK3A (GSK3 alpha) ZLYTE 43 43 43
100 Km app GSK3B (GSK3 beta) ZLYTE 23 25 24
100 Km app IRAK4 ZLYTE 3 -14 -6
100 Km app ITK ZLYTE 17 12 14
100 Km app JAK1 ZLYTE -10 -6 -8
100 Km app LCK ZLYTE 10 8 9
100 100 MAP2K1 (MEK1) ZLYTE -20 -6 -13
100 100 MAP2K2 (MEK2) ZLYTE 13 6 9
100 Km app MAPK1 (ERK2) ZLYTE 5 6 6
100 Km app MAPK14 (p38 alpha) Direct ZLYTE 2 4 3
100 Km app MAPK3 (ERK1) ZLYTE -8 1 -3
100 100 MAPK8 (JNK1) ZLYTE 4 21 12
100 100 MAPK9 (JNK2) ZLYTE 3 -5 -1
100 Km app MAPKAPK2 ZLYTE -2 2 0
100 Km app MARK1 (MARK) ZLYTE 20 13 17
100 Km app PAK6 ZLYTE 1 -9 -4
100 Km app PRKACA (PKA) ZLYTE -5 -5 -5
100 Km app PRKCA (PKC alpha) ZLYTE -2 2 0
100 Km app PRKCB1 (PKC beta I) ZLYTE -10 -10 -10
100 Km app PRKCD (PKC delta) ZLYTE -2 -12 -7
100 Km app PRKCE (PKC epsilon) ZLYTE 4 3 3
100 Km app PRKCZ (PKC zeta) ZLYTE -3 -2 -3
100 100 RAF1 (cRAF) Y340D Y341D ZLYTE 10 11 10
100 Km app ROCK1 ZLYTE -9 -6 -7
100 Km app ROCK2 ZLYTE 3 1 2
100 Km app RPS6KA1 (RSK1) ZLYTE -3 7 2
100 Km app RPS6KB1 (p70S6K) ZLYTE -3 -10 -6
100 Km app SRC ZLYTE 8 6 7


[0111] As it is evident from the data reported, there was no activity on 58 kinases involved in the Akt pathway, with the only exception for Aurora A and GSK3 which resulted to be inhibited with percentage values of 38%, 43% at 100nM of the tested compound.

[0112] In order to study more in depth the biological properties of the new compounds and to correlate the PDK1 inhibition activity to the in vitro antiproliferative properties, the compounds IB35, SA23 and SA16 were further investigated in a series of biological in vitro assays on U87MG cell lines and stem cells isolated from U87MG cells.

[0113] GBM cell-line culture and GSC isolation. The U87MG cell line was obtained from the National Institute for Cancer Research of Genoa (Italy) and cultured in DMEM 10% FBS and 2 mM glutamine. To isolate GSCs, approximately 2.0 x 106 cells were suspended in 1 mL of a defined serum-free Neural Stem Cell (NSC) medium (Daniele, S., et al., Modulation of A1 and A2B adenosine receptor activity: a new strategy to sensitise glioblastoma stem cells to chemotherapy. Cell death & disease, 2014. 5(11): p. e1539). After 3-4 days of culture, the neurospheres were collected, suspended in NSC medium, dissociated into single cells, and plated for the assays. For the long-term treatment of cells, NSC or complete medium containing drugs was replaced every two to three days. Cell proliferation assays of GBM cells and GSCs. The human U87MG cells or GSCs were seeded at a density of 3 x 103 cells/well. After 24 h, the cells were treated from one to seven days with fresh growth medium containing different concentrations of SA16, SA23 or IB35. Following the treatment period, cell proliferation was determined using the MTS assay according to manufacturer's instruction. The absorbance of formazan at 490 nM was measured in a colorimetric assay with an automated plate reader (Victor Wallac 2, Perkin Elmer). The results were calculated by subtracting the mean background from the values obtained from each evaluation and were expressed as the percentage of the control (untreated cells). Sigmoid dose-response curve was generated, from which the IC50 values were derived.

[0114] Annexin V and 7-AAD staining in U87MG cells and in GSCs. Dual staining with Annexin V coniugated to fluorescein-isothiocyanate (FITC) and 7-amino-actinomysin (7-AAD) was performed using the commercially available kit (Muse Annexin V and Dead Cell Kit; Merck KGaA, Darmstadt, Germany). U87MG cells or GSCs were treated with DMSO (control), SA16, SA23 or IB35 for 72h or seven days, respectively. At the end of the treatment periods, the percentages of living, apoptotic and dead cells were acquired and analysed by Muse™ Cell Analyzer as previously described (Daniele, S., et al., Combined inhibition of AKT/mTOR and MDM2 enhances Glioblastoma Multiforme cell apoptosis and differentiation of cancer stem cells. Sci. Rep., 2015. 5.).

[0115] PDK1 activity in U87MG cells and in GSCs. U87MG cells were cultured in 96-well microplates (5.000 cells/well), and treated for different times with 10 µM SA16, SA23 or IB35. At the end of the treatment period, the GSCs were centrifuged at 500 x g for 3 minutes; cells were washed twice using fresh saline, and rapidly fixed with 4% (for adherent U87MG cells) or 8% (for suspension GSCs) formaldehyde to preserve activation of specific protein modification. The activity of PDK1 was assessed measuring the levels of phosphorylated AKT on Thr308, using a specific primary antibodies. The subsequent incubation with a secondary HRP-conjugated antibody and the developing solution allowed the colorimetric quantification of the levels of phosphorylated protein. The relative number of cells in each well was then determined using the Crystal-Violet assay. The results were calculated by subtracting the mean background value from the values obtained under each test condition: values were normalised to the number of cells in each well and were expressed as the percentages of the control (untreated cells) values.

[0116] Wound healing migration assay U87MG cells were plated (1x105) onto six-well plates up to form a confluent monolayer, and treated for 72 h with 10 µM SA16, SA23 or IB35. The cell monolayer was then scratched in a straight line to make a 'scratch wound' with a 0.2-ml pipette tip and the cell debris was removed by washing the cells with phosphate-buffered saline. RPMI medium supplemented with 1 % FBS was added, and images of the closure of the scratch were captured at 0, 6, and 24 h.

[0117] Statistical analysis. The non-linear multipurpose curve-fitting program GraphPad Prism (GraphPad Software Inc., San Diego, CA) was used for data analysis and graphic presentations. All data are presented as the mean ± SEM. Statistical analysis was performed by one-way analysis of variance (ANOVA) with Bonferroni's corrected t-test for post-hoc pair-wise comparisons. P<0.05 was considered statistically significant.

Results


Effects of the PDK1 inhibitors on U87MG cell proliferation.



[0118] As representative GBM cell line, the above U87MG cells were used; this human cell line resulted an appropriate model to study the effects of PDK1 inhibition, because it is deficient for the tumour suppressor phosphatase and tensin homologue (PTEN), a negative regulator of the PI3K/AKT pathway (Wang, S.I., et al., Somatic mutations of PTEN in glioblastoma multiforme. Cancer research, 1997. 57(19): p. 4183-4186). To examine the effects of SA16, SA23 and IB35 on GBM cell growth/survival, U87MG cells were incubated with different concentrations of the new compounds (1 nM-10 µM) for 24 and 72 h. Specifically, U87MG cells were treated in complete medium with different concentrations of SA16, SA23 or IB35 (1 nM-10 µM) for 24 h (A) or 72 h (B). At the end of treatment, cell proliferation was measured using the MTS assay. The data are expressed as a percentage with respect to that of untreated cells (control), which was set to 100%, and are the mean values ± SEM of three independent experiments, each performed in duplicate. The significance of the differences reported in figures 1 and 2 was determined with a one-way ANOVA with Bonferroni post-test (*p<0.05, **p<0.01, *** p<0.001 vs. control cells).

[0119] After 24 h (Figure 1), the three compounds induced only a modest inhibition of U87MG cell proliferation; the higher effect was observed with IB35 (41% of inhibition, figure 1). In contrast, after 72h all compounds significantly decreased U87MG cell proliferation, in a concentration-dependent manner, yielding IC50 values of 449.7 ± 46.2 nM (IB35), 2.05 ± 0.19 µM (SA16) and 1.17 ± 0,10 µM (SA23) (Figure 2). The ranking of IC50 values of the new compounds on U87MG cells reflected the affinity ranking towards recombinant PDK1, thus confirming that the anti-proliferative activities are mediated by PDK1 inhibition.

Effect of PDK1 inhibitors on the induction of U87MG apoptosis.



[0120] It was then investigated whether the reduction in cell proliferation elicited by the PDK1 inhibitors could be associated with apoptosis. U87MG cells were treated for 72 h with DMSO (control), or 10 µM SA16, SA23 or IB35. At the end of the treatment period, the cells were collected, and the level of phosphatidylserine externalisation was evaluated using the Annexin V-staining protocol, as described above (Figure 3). In Figure 4 the data are expressed as the percentage of apoptotic cells (the data for the early-stage apoptotic cells shown in white, and the data for the late-stage apoptotic/necrotic cells shown in grey) versus the total number of cells. The data shown represented the mean ± SEM of three different experiments. The significance of the differences was determined with a one-way ANOVA with Bonferroni post-test (***p<0.001 vs. control).

[0121] Treatment of U87MG cells with SA16, SA23 and IB35 (10 µM) for 72 h induced a significant phosphatidylserine externalization, both in the absence (early apoptosis), or in the presence of 7-amino-actinomysin binding to DNA (late apoptosis/death) (Figures 3 and 4). Consistent with the data obtained in the MTS assay, IB35 showed the highest degree of GBM apoptosis (percentage of total apoptotic cells: 23.0 ± 1.9).

Effects of SA16, SA23 and IB35 on PDK1 activity in U87 MG cells.



[0122] To assess whether SA16, SA23 and IB35 could effectively inhibit the AKT/PDK1 pathway in U87MG cells, U87MG were treated for different times with 10 µM of each inhibitor; following incubation, PDK1 activity was assessed evaluating AKT phosphorylation at Thr308. As reported in literature, U87MG cells displayed a constitutive high level of phosphorylated AKT at both the T308 and Ser473 regulatory sites, in line with a cell profile of cancer cells deficient for PTEN (Gonzalez-Angulo, A.M., et al., SU2C Phase Ib Study of Paclitaxel and MK-2206 in Advanced Solid Tumors and Metastatic Breast Cancer. Journal of the National Cancer Institute, 2015. 107(3): p. dju493; Zinda, M.J., C.J. Vlahos, and M.T. Lai, Ceramide induces the dephosphorylation and inhibition of constitutively activated Akt in PTEN negative U87mg cells. Biochemical and biophysical research communications, 2001. 280(4): p. 1107-1115). U87MG were hence treated for the indicated times (0-120 min) with complete medium containing DMSO (control), or 10 µM SA16, SA23 or IB35. At the end of the treatment periods, the levels of (T308)AKT phosphorylation was evaluated using an ELISA kit, as described above. The data reported in Figure 5 were expressed as the percentage of phosphorylated (T308)AKT relative to those of untreated cells (control), which were set at 100%, and were the mean values ± SEM of three independent experiments performed in triplicate. As depicted in Figure 5, SA23 and IB35, tested at 10 µM, significantly inhibited AKT phosphorylation at Thr308, in a time-dependent manner, with a peak of inhibition after 120 min, confirming the compounds were able to block PDK1 activity. In contrast, SA16 elicited a biphasic kinetic of (T308)AKT inhibition, showing peaks after 5 min and 120 min of treatment (Figure 5).

Effects of PDK1 inhibitors on the cell migration.



[0123] To assess whether the inhibition of PDK1 activity could be associated to a cell migration block, a scratch wound assay was performed. Representative microscopic images are shown in Figure 6. U87MG cells were treated for 72 h with DMSO (control), or 10 µM SA16, SA23 and IB35. Then the cell monolayer was scratched (time zero), and cells were allowed to growth in fresh medium. Representative micrographs were taken after 6 h and 24 h from the scratch (Figure 6). The gap area (Figure 7) was measured after 6 h and 24 h from the scratch; the counts were the mean values ± SEM of three independent experiments. The significance of the differences was determined using a one-way ANOVA with the Bonferroni post-test (**P<0.05, ***P<0.001 vs control; ###P<0.001 vs respective gap area at 6 h from the scatch).

[0124] Quantitative analysis of gap area (Figure 7) demonstrated that the treatment of U87MG cells with PDK1 inhibitors significantly inhibit cell migration, both after 6 h and 24 h from the scratch. These results confirmed that a PDK1 inhibition leads to a suppression of tumour cell migration.

Effects of SA16, SA23 and IB35 treatment on GSC proliferation



[0125] The inhibition of PDK1 has been reported as potentially effective therapeutic approach to reduce self-renewal and propagation of GSCs (Signore, M., et al., Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo. Cell death & disease, 2014. 5(5): p. e1223). On this basis, the effects of SA16, SA23 and IB35 on GSCs, isolated from U87MG cells as previously reported, were evaluated (Daniele, S., et al., Modulation of A1 and A2B adenosine receptor activity: a new strategy to sensitise glioblastoma stem cells to chemotherapy. Cell death & disease, 2014. 5(11): p. e1539). U87MG-derived GSCs were incubated with the indicated concentrations of IB35, SA23 or SA16 for four days (Figure 8) or seven days (Figure 9). At the end of the treatment periods, cell proliferation was measured using the MTS assay. The data were expressed as a percentage with respect to that of untreated cells (control), which was set to 100%, and are the mean values ± SEM of three independent experiments, each performed in duplicate. IC50 values after seven days of treatment were calculated from sigmoid dose-response curve (Figure 9). The significance of the differences was determined with a one-way ANOVA with Bonferroni post-test (** p<0.01, *** p<0.001 vs. control).

[0126] When GSCs were incubated with IB35 and SA23, a significant inhibition of cell proliferation occurred, starting from four days of treatment (Figure 8). After seven days of treatment, the compounds induced a concentration-dependent inhibition of GSC proliferation, yielding IC50 values of 3,36 ± 0,40 nM (IB35), 0,30 ± 0,04 nM (SA23) and 5,47 ± 0,10 nM (SA16) (Figure 9). These data confirmed that the PDK1 inhibitors are able to block GSC proliferation.

Effects of PDK1 inhibitors on GSC apoptosis.



[0127] It was investigated if the reduction of cell proliferation elicited by the two compounds could be associated to cell apoptosis. GSCs were treated for 7 days with NSC medium containing DMSO (control), or 10 µM of IB35, SA16 or SA23 for seven days. At the end of treatments, the cells were collected and the degree of phosphatidylserine externalisation was evaluated using the Annexin V protocol, as above described (figure 10). The data were expressed as the percentage of apoptotic cells (early-apoptotic in white, late-apoptotic/necrotic in grey) relative to the total number of cells and represented in Figure 11. The data were the mean values ± SEM of three different experiments. The significance of the differences was determined with a one-way ANOVA with Bonferroni post-test (*** p<0.001 vs. control).

[0128] When Annexin V staining was measured after 7 days of GSC treatment, all compounds induced a significant phosphatidylserine externalization, both in the absence (early apoptosis), or in the presence of 7-amino-actinomysin 11 binding to DNA (late apoptosis/death) (Figures 10 and 11). As in U87MG cells, IB35 showed the highest degree of GBM apoptosis (percentage of total apoptotic cells: 38,5 ± 3,9).

Effects of SA16, SA23 and IB35 PDK1 activity in GSCs.



[0129] The effects of the new compounds on PDK1 activity were investigated by ELISA assays also in GSCs. U87MG-derived CSCs were treated for the indicated times (0-120 min) with NSC medium containing DMSO (control), or 10 µM IIB35, SA23 or SA16. At the end of the treatment periods, the levels of AKT phosphorylation on Thr308 were evaluated using an ELISA assay, as above described. The data were expressed as the percentage of phosphorylated AKT relative to those of untreated cells (control), which were set at 100%, and were the mean values ± SEM of three independent experiments performed in triplicate. The data are represented in Figure 12. The significance of differences was performed using one-way ANOVA with Bonferroni post-test (* p< 0.05, ** p< 0.01, *** p<0.001 vs. control). Consistent with the data obtained in U87MG cells, SA23 and IB35, tested at 10 µM, significantly inhibited AKT phosphorylation at Thr308, in a time-dependent manner, with a peak of inhibition after 120 min (Figure 12). In contrast, as evidenced in U87MG cells, SA16 elicited a biphasic kinetic of AKT inhibition, showing peaks after 5 min and 120 min of treatment. Of note, the percentages of PDK1 inhibition were significantly higher in GSCs with respect to U87MG cells (peak of inhibition for IB35: 54.0 ± 5.2 in U87MG cells; 80.4 ± 3.7 in GSCs; peak of inhibition for SA16: 33.3 ± 4.5 in U87MG cells; 74.8 ± 3.0 in GSCs; peak of inhibition for SA23: 48.1± 5.0 in U87MG cells; 69.0 ± 4.5 in GSCs.

Comparison of antiproliferative activities with a known drug in GBM and GSCs



[0130] The compounds of the invention IB35, SA16 and SA23 were compared with Everolimus (dihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl]-19,30-dimethoxy-15, 17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.0 hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone) a gold standard drug of Novartis for targeted-therapy (now in phase I of clinical trials for GBM) (Daniele, S., et al., Combined inhibition of AKT/mTOR and MDM2 enhances Glioblastoma Multiforme cell apoptosis and differentiation of cancer stem cells. Sci. Rep., 2015. 5).

[0131] The results are reported in the table below.
CompoundIC50 (nM) PDK1 directIC50 U87MG (nM)IC50 (nM) GSC
IB35 112 449.7 ± 46,2 3.36 ± 0.40
SA16 416 2050 ± 190 5.47 ± 0.10
SA23 1520 1170 ± 100 0.30 ± 0.04
Everolimus (Novartis) - 50.0 ± 2,8 15.0 ± 1.2


[0132] The data in table show that even if the IB35 SA16 and SA23 prove to inhibit cell growth on U87 cell line, the potency is lower than Everolimus. On the contrary, the antiproliferative activity against GSC is from 2- to 50-fold higher than Everolimus, indicating that IB35, SA16 and SA23 are more capable in accelerating the induction of apoptosis and thus enhance the inhibition of GSC viability with respect to Everolimus.

[0133] From the experimental biological part reported above, the compounds JJ31, IB32, IB35, SA16 and SA23 show to inhibit the PDK1 enzyme with IC50 values in the range of nM to µM.

[0134] The ranking of IC50 value on recombinant PDK1 reflected the affinity ranking towards U87MG cell lines, thus confirming that the antiproliferative activity was mediated by PDK1. IB35, SA16 and SA23 inhibited PDK1 constitutive activity in U87MG cells; as a result, the new compounds decreased cell viability, and triggered apoptosis. Moreover, the inhibition of cell viability was long-lasting (72h). In the wound scratch assay, PDK1 inhibitors showed to significantly inhibit cell migration, both after 6 h and 24 h from the scratch. These results confirmed that a PDK1 inhibition leads to a suppression of tumour cell migration.

[0135] Finally, the new compounds were characterized in glioma stem cells (GSCs) isolated from U87MG cells. The results obtained indicated that new compounds induced a time- and concentration-dependent inhibition of GSC proliferation and triggered apoptosis, thus confirming that PDK1 inhibitors were able to block GSC proliferation.


Claims

1. A 2-oxo-1,2-dihydropyridine-3-carboxamide compound of Formula (I)

wherein

m is 0 or 1

n is 0 or 1

A is selected from the group consisting of (-NH-CO-CH2-), (-NH-CO-CH(Ph)-), (-NH-CO-CH2-CH2-), (-NH-CO-CH2-CH2-CH2-) and (-NH-CO-Ph-); and

B is CH-D, where D is selected from the group consisting of thienyl, phenyl, imidazolyl, being D optionally substituted with a halogen,

or a pharmaceutical salt thereof for use in the treatment of pathologies requiring the use of an inhibitor of PDK1 enzyme.
 
2. The compound for use of claim 1, wherein m is 0 and n is 1.
 
3. The compound for use of claim 1, wherein m is 1 and n is 1.
 
4. The compound for use of claim 1, wherein A is (-NH-CO-CH2-), (-NH-CO-CH2-CH2-CH2-), (-NH-CO-CH2-CH2), or (-NH-CO-Ph-) or (-NH-CO-CH(Ph)-),.
 
5. The compound for use of claim 4, wherein A is (-NH-CO-CH2-) or (-NH-CO-CH2-CH2).
 
6. The compound for use of anyone of claims 1, 4-5 wherein n is 1 and B is CH-D, where D is imidazolyl, preferably 1H-imidazol-5-yl.
 
7. The compound for use of claim 1, wherein said compound is selected from the group consisting of (Z)-N-(3-((1H-imidazol-5-yl)methylene)-2-oxoindolin-5-yl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide, 1-(3,4-difluorobenzyl)-2-oxo-N-(2-oxo-2-((2-oxoindolin-5-yl)amino)ethyl)-1 ,2-dihydropyridine-3-carboxamide, (E/Z)-1-(3,4-difluorobenzyl)-2-oxo-N-(2-oxo-2-((2-oxo-3-(thiophen-2-ylmethylene)indolin-5-yl)amino)ethyl)-1,2-dihydropyridine-3-carboxamide, (Z)-N-(2-((3-((1H-imidazol-5-yl)methylene)-2-oxoindolin-5-yl)amino)-2-oxoethyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide, (Z)-(R)-N-(2-((3-((1H-imidazol-5-yl)methylene)-2-oxoindolin-5-yl)amino)-2-oxo-1-phenylethyl)-1 -(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide, (Z)-(R)-N-(2-((3-((1H-imidazol-5-yl)methylene)-2-oxoindolin-2-yl)amino)-2-oxo-1-phenylethyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide, (E/Z)-1-(3,4-difluorobenzyl)-2-oxo-N-(3-oxo-3-((2-oxo-3-(thiophen-2-ylmethylene)indolin-5-yl)amino)propyl)-1,2-dihydropyridine-3-carboxamide, (Z)-N-(3-((3-((1H-imidazol-5-yl)methylene)-2-oxoindolin-5-yl)amino)-3-oxopropyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide, (E/Z)-1-(3,4-difluorobenzyl)-N-(3-((3-(4-fluorobenzylidene)-2-oxoindolin-5-yl)amino)-3-oxopropyl)-2-oxo-1,2-dihydropyridine-3-carboxamide, (Z/E)-N-(3-((3-((1H-imidazol-2-yl)methylene)-2-oxoindolin-5-yl)amino)-3-oxopropyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide, (Z)-N-(3-((3-((1H-imidazol-5-yl)methylene)-2-oxoindolin-5-yl)carbamoyl)phenyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide, (E/Z)-1-(3,4-difluorobenzyl)-2-oxo-N-(3-((2-oxo-3-(thiophen-2-ylmethylene)indolin-5-yl)carbamoyl)phenyl)-1,2-dihydropyridine-3-carboxamide, (Z)-N-(4-((3-((1H-imidazol-5-yl)methylene)-2-oxoindolin-5-yl)amino)-4-oxobutyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide and (E/Z)-1-(3,4-difluorobenzyl)-2-oxo-N-(4-oxo-4-((2-oxo-3-(thiophen-2-ylmethylene)indolin-5-yl)amino)butyl)-1,2-dihydropyridine-3-carboxamide.
 
8. The compound for use of claim 7, wherein said compound is selected from the group (Z)-N-(2-((3-((1H-imidazol-5-yl)methylene)-2-oxoindolin-5-yl)amino)-2-oxoethyl)-1 -(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide, (Z)-(R)-N-(2-((3-((1H-imidazol-5-yl)methylene)-2-oxoindolin-5-yl)amino)-2-oxo-1-phenylethyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide, (Z)-(R)-N-(2-((3-((1H-imidazol-5-yl)methylene)-2-oxoindolin-2-yl)amino)-2-oxo-1-phenylethyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide, (Z)-N-(3-((3-((1H-imidazol-5-yl)methylene)-2-oxoindolin-5-yl)carbamoyl)phenyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide, and (Z)-N-(4-((3-((1H-imidazol-5-yl)methylene)-2-oxoindolin-5-yl)amino)-4-oxobutyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide.
 
9. The compound for use of claim 8, wherein the compound of is (Z)-N-(2-((3-((1H-imidazol-5-yl)methylene)-2-oxoindolin-5-yl)amino)-2-oxoethyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide.
 
10. The compound for use of anyone of claims 1-9, wherein the pathology that require a PDK1 inhibitor is a cancer, preferably glioblastoma.
 
11. A 2-oxo-1,2-dihydropyridine-3-carboxamide compound of Formula (II)

wherein

n is 0 or 1

B is CH-D, where D is selected from the group consisting of thienyl, phenyl, imidazolyl, being D optionally substituted with a halogen; and

A is selected from the group consisting of (-NH-CO-CH2-), (-NH-CO-CH(Ph)-), (-NH-CO-CH2-CH2-), (-NH-CO-CH2-CH2-CH2-) and (-NH-CO-Ph-)

or a pharmaceutical salt thereof.
 
12. The compound of claim 11, wherein A is selected from the group consisting of (-NH-CO-CH2-), (-NH-CO-CH2-CH2-), (-NH-CO-CH2-CH2-CH2-) and (-NH-CO-Ph-).
 
13. The compound of claim 12 ,wherein A is (-NH-CO-CH2-).
 
14. The compound of anyone of claims 11-13, wherein n is 1 and B is CH-D, where D is imidazolyl, preferably 1H-imidazol-5-yl.
 
15. The compound of claim 11, wherein said compound is selected from the group consisting of (E/Z)-1-(3,4-difluorobenzyl)-2-oxo-N-(2-oxo-2-((2-oxo-3-(thiophe-2-ylmethylene)indolin-5-yl)amino)ethyl)-1,2-dihydropyridine-3-carboxamide, (Z)-N-(2-((3-((1H-imidazol-5-yl)methylene)-2-oxoindolin-5-yl)amino)-2-oxoethyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydro pyridine-3-carboxamide, (Z)-(R)-N-(2-((3-((1H-imidazol-5-yl)methylene)-2-oxoindolin-5-yl)amino)-2-oxo-1-phenylethyl)-1-(3,4-difluorobenzyl)-2-oxo-1 ,2-dihydropyridine-3-carboxamide, (Z)-(R)-N-(2-((3-((1H-imidazol-5-yl)methylene)-2-oxoindolin-2-yl)amino)-2-oxo-1-phenylethyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide, (E/Z)-1-(3,4-difluorobenzyl)-2-oxo-N-(3-oxo-3-((2-oxo-3-(thiophen-2-ylmethylene)indolin-5-yl)amino)propyl)-1,2-dihydropyridine-3-carboxamide, (Z)-N-(3-((3-((1H-imidazol-5-yl)methylene)-2-oxoindolin-5-yl)amino)-3-oxopropyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide, (E/Z)-1-(3,4-difluorobenzyl)-N-(3-((3-(4-fluorobenzylidene)-2-oxoindolin-5-yl)amino)-3-oxopropyl)-2-oxo-1,2-dihydropyridine-3-carboxam ide, (Z/E)-N-(3-((3-((1H-imidazol-2-yl)methylene)-2-oxoindolin-5-yl)amino)-3-oxopropyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide, (Z)-N-(3-((3-((1H-imidazol-5-yl)methylene)-2-oxoindolin-5-yl)carbamoyl)phenyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide, (E/Z)-1-(3,4-difluorobenzyl)-2-oxo-N-(3-((2-oxo-3-(thiophen-2-ylmethylene)indolin-5-yl)carbamoyl)phenyl)-1,2-dihydropyridine-3-carboxamide, (Z)-N-(4-((3-((1H-imidazol-5-yl)methylene)-2-oxoindolin-5-yl)amino)-4-oxobutyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide and (E/Z)-1-(3,4-difluorobenzyl)-2-oxo-N-(4-oxo-4-((2-oxo-3-(thiophen-2-ylmethylene)indolin-5-yl)amino)butyl)-1,2-dihydropyridine-3-carboxamide.
 
16. The compound of claim 15, wherein said compound is selected from the group (Z)-N-(2-((3-((1H-imidazol-5-yl)methylene)-2-oxoindolin-5-yl)amino)-2-oxoethyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide, (Z)-(R)-N-(2-((3-((1H-imidazol-5-yl)methylene)-2-oxoindolin-5-yl)amino)-2-oxo-1-phenylethyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide and (Z)-(R)-N-(2-((3-((1H-imidazol-2-yl)methylene)-2-oxoindolin-5-yl)amino)-2-oxo-1-phenylethyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide, (Z)-N-(3-((3-((1H-imidazol-5-yl)methylene)-2-oxoindolin-5-yl)carbamoyl)phenyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide, and (Z)-N-(4-((3-((1H-imidazol-5-yl)methylene)-2-oxoindolin-5-yl)amino)-4-oxobutyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide.
 
17. The compound of claim 14, wherein the compound of is (Z)-N-(2-((3-((1H-imidazol-5-yl)methylene)-2-oxoindolin-5-yl)amino)-2-oxoethyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydro pyridine-3-carboxamide.
 
18. A 2-oxo-1,2-dihydropyridine-3-carboxamide compound of anyone of claims 11 - 17 for use as a medicament.
 
19. A pharmaceutical composition comprising a 2-oxo-1,2-dihydropyridine-3-carboxamide compound of anyone of claims 11-18 and a pharmaceutically acceptable carrier.
 
20. A 2-oxo-1,2-dihydropyridine-3-carboxamide compound of anyone of claims 11 - 17 for use in the treatment of pathologies which require an inhibitor of PDK1 enzyme.
 
21. The 2-oxo-1,2-dihydropyridine-3-carboxamide compound for use of claim 20, wherein the pathology is selected from the group consisting of diabetes, neurodegenerative diseases such as Alzheimer's and Prion Diseases, and tumours such as breast, and pancreatic cancers and glioblastoma.
 
22. The 2-oxo-1,2-dihydropyridine-3-carboxamide compound for use of claim 21, wherein the pathology is a cancer, preferably glioblastoma (GBM).
 


Ansprüche

1. 2-Oxo-1,2-dihydropyridin-3-carboxamid-Verbindung der Formel (I)

wobei

m 0 oder 1 ist

n 0 oder 1 ist

A aus der Gruppe ausgewählt ist, die aus (-NH-CO-CH2-), (-NH-CO-CH(Ph)-), (-NH-CO-CH2-CH2-), (-NH-CO-CH2-CH2-CH2-) und (-NH-CO-Ph-) besteht; und

B CH-D ist, wobei D aus der Gruppe ausgewählt ist, die aus Thienyl, Phenyl, Imidazolyl besteht, wobei D gegebenenfalls mit einem Halogen substituiert ist,

oder ein pharmazeutisches Salz davon zur Verwendung bei der Behandlung von Pathologien, die die Verwendung eines Hemmers des PDK1-Enzyms erforderlich machen.
 
2. Verbindung zur Verwendung gemäß Anspruch 1, wobei m 0 ist und n 1 ist.
 
3. Verbindung zur Verwendung gemäß Anspruch 1, wobei m 1 ist und n 1 ist.
 
4. Verbindung zur Verwendung gemäß Anspruch 1, wobei A (-NH-CO-CH2-),(-NH-CO-CH2-CH2-CH2-), (-NH-CO-CH2-CH2), oder (-NH-CO-Ph-) oder (-NH-CO-CH(Ph)-) ist.
 
5. Verbindung zur Verwendung gemäß Anspruch 4, wobei A (-NH-CO-CH2-) oder (-NH-CO-CH2-CH2) ist.
 
6. Verbindung zur Verwendung gemäß einem der Ansprüche 1, 4-5, wobei n 1 ist und B CH-D ist, wobei D Imidazolyl, vorzugsweise 1H-Imidazol-5-yl ist.
 
7. Verbindung zur Verwendung gemäß Anspruch 1, wobei die Verbindung ausgewählt ist aus der Gruppe, die aus (Z)-N-(3-((1H-Imidazol-5-yl)methylen)-2-oxoindolin-5-yl)-1-(3,4-difluorbenzyl)-2-oxo-1 ,2-dihydropyridin-3-carboxamid, 1-(3,4-Difluorbenzyl)-2-oxo-N-(2-oxo-2-((2-oxoindolin-5-yl)amino)ethyl)-1,2-dihydropyridin-3-carboxamid, (E/Z)-1-(3,4-Difluorbenzyl)-2-oxo-N-(2-oxo-2-((2-oxo-3-(thiophen-2-ylmethylen)indolin-5-yl)amino)ethyl)-1,2-dihydropyridin-3-carboxamid, (Z)-N-(2-((3-((1H-Imidazol-5-yl)methylen)-2-oxoindolin-5-yl)amino)-2-oxoethyl)-1-(3,4-difluorbenzyl)-2-oxo-1,2-dihydropyridin-3-carboxamid, (Z)-(R)-N-(2-((3-((1H-Imidazol-5-yl)methylen)-2-oxoindolin-5-yl)amino)-2-oxo-1-phenylethyl)-1 -(3,4-difluorbenzyl)-2-oxo-1,2-dihydropyridin-3-carboxamid, (Z)-(R)-N-(2-((3-((1H-Imidazol-5-yl)methylen)-2-oxoindolin-2-yl)amino)-2-oxo-1-phenylethyl)-1-(3,4-difluorbenzyl)-2-oxo-1,2-dihydropyridin-3-carboxamid, (E/Z)-1-(3,4-Difluorbenzyl)-2-oxo-N-(3-oxo-3-((2-oxo-3-(thiophen-2-ylmethylen)indolin-5-yl)amino)propyl)-1,2-dihydropyridin-3-carboxamid, (Z)-N-(3-((3-((1H-Imidazol-5-yl)methylen)-2-oxoindolin-5-yl)amino)-3-oxopropyl)-1-(3,4-difluorbenzyl)-2-oxo-1,2-dihydropyridin-3-carboxamid, (E/Z)-1-(3,4-Difluorbenzyl)-N-(3-((3-(4-fluorbenzyliden)-2-oxoindolin-5-yl)amino)-3-oxopropyl)-2-oxo-1,2-dihydropyridin-3-carboxamid, (Z/E)-N-(3-((3-((1H-Imidazol-2-yl)methylen)-2-oxoindolin-5-yl)amino)-3-oxopropyl)-1-(3,4-difluorbenzyl)-2-oxo-1,2-dihydropyridin-3-carboxamid, (Z)-N-(3-((3-((1H-imidazol-5-yl)methylen)-2-oxoindolin-5-yl)carbamoyl)phenyl)-1-(3,4-difluorbenzyl)-2-oxo-1,2-dihydropyridin-3-carboxamid, (E/Z)-1-(3,4-Difluorbenzyl)-2-oxo-N-(3-((2-oxo-3-(thiophen-2-ylmethylen)indolin-5-yl)carbamoyl)phenyl)-1,2-dihydropyridin-3-carboxamid, (Z)-N-(4-((3-((1H-Imidazol-5-yl)methylen)-2-oxoindolin-5-yl)amino)-4-oxobutyl)-1-(3,4-difluorbenzyl)-2-oxo-1,2-dihydropyridin-3-carboxamid und (E/Z)-1-(3,4-Difluorbenzyl)-2-oxo-N-(4-oxo-4-((2-oxo-3-(thiophen-2-ylmethylen)indolin-5-yl)amino)butyl)-1,2-dihydropyridin-3-carboxamid besteht.
 
8. Verbindung zur Verwendung gemäß Anspruch 7, wobei die Verbindung ausgewählt ist aus der Gruppe (Z)-N-(2-((3-((1H-Imidazol-5-yl)methylen)-2-oxoindolin-5-yl)amino)-2-oxoethyl)-1-(3,4-difluorbenzyl)-2-oxo-1,2-dihydropyridin-3-carboxamid, (Z)-(R)-N-(2-((3-((1H-Imidazol-5-yl)methylen)-2-oxoindolin-5-yl)amino)-2-oxo-1 -phenylethyl)-1 -(3,4-difluorbenzyl)-2-oxo-1,2-dihydropyridin-3-carboxamid, (Z)-(R)-N-(2-((3-((1H-Imidazol-5-yl)methylen)-2-oxoindolin-2-yl)amino)-2-oxo-1 -phenylethyl)-1-(3,4-difluorbenzyl)-2-oxo-1,2-dihydropyridin-3-carboxamid, (Z)-N-(3-((3-((1H-Imidazol-5-yl)methylen)-2-oxoindolin-5-yl)carbamoyl)phenyl)-1-(3,4-difluorbenzyl)-2-oxo-1,2-dihydropyridin-3-carboxamid und (Z)-N-(4-((3-((1H-Imidazol-5-yl)methylen)-2-oxoindolin-5-yl)amino)-4-oxobutyl)-1-(3,4-difluorbenzyl)-2-oxo-1 ,2-dihydropyridin-3-carboxamid.
 
9. Verbindung zur Verwendung gemäß Anspruch 8, wobei die Verbindung von (Z)-N-(2-((3-((1H-Imidazol-5-yl)methylen)-2-oxoindolin-5-yl)amino)-2-oxoethyl)-1-(3,4-difluorbenzyl)-2-oxo-1,2-dihydropyridin-3-carboxamid ist.
 
10. Verbindung zur Verwendung gemäß einem der Ansprüche 1-9, wobei die Pathologie, die einen PDK1-Hemmer erforderlich macht, ein Krebs, vorzugsweise Glioblastom, ist.
 
11. 2-Oxo-1,2-dihydropyridin-3-carboxamid-Verbindung der Formel (II)

wobei

n 0 oder 1 ist

B CH-D ist, wobei D aus der Gruppe ausgewählt ist, die aus Thienyl, Phenyl, Imidazolyl besteht, wobei D gegebenenfalls mit einem Halogen substituiert ist; und

A aus der Gruppe ausgewählt ist, die aus (-NH-CO-CH2-), (-NH-CO-CH(Ph)-), (-NH-CO-CH2-CH2-), (-NH-CO-CH2-CH2-CH2-) und (-NH-CO-Ph-) besteht

oder ein pharmazeutisches Salz davon.
 
12. Verbindung gemäß Anspruch 11, wobei A aus der Gruppe ausgewählt ist, die aus (-NH-CO-CH2-), (-NH-CO-CH2-CH2-), (-NH-CO-CH2-CH2-CH2-) und (-NH-CO-Ph-) besteht.
 
13. Verbindung gemäß Anspruch 12, wobei A (-NH-CO-CH2-) ist.
 
14. Verbindung gemäß einem der Ansprüche 11-13, wobei n 1 ist und B CH-D ist, wobei D Imidazolyl, vorzugsweise 1H-Imidazol-5-yl ist.
 
15. Verbindung gemäß Anspruch 11, wobei die Verbindung ausgewählt ist aus der Gruppe, die aus (E/Z)-1-(3,4-Difluorbenzyl)-2-oxo-N-(2-oxo-2-((2-oxo-3-(thiophe-2-ylmethylen)indolin-5-yl)amino)ethyl)-1,2-dihydropyridin-3-carboxamid, (Z)-N-(2-((3-((1H-Imidazol-5-yl)methylen)-2-oxoindolin-5-yl)amino)-2-oxoethyl)-1-(3,4-difluorbenzyl)-2-oxo-1,2-dihydropyridin-3-carboxamid, (Z)-(R)-N-(2-((3-((1H-Imidazol-5-yl)methylen)-2-oxoindolin-5-yl)amino)-2-oxo-1 -phenylethyl)-1 -(3,4-difluorbenzyl)-2-oxo-1,2-dihydropyridin-3-carboxamid, (Z)-(R)-N-(2-((3-((1H-Imidazol-5-yl)methylen)-2-oxoindolin-2-yl)amino)-2-oxo-1-phenylethyl)-1 -(3,4-difluorbenzyl)-2-oxo-1,2-dihydropyridin-3-carboxamid, (E/Z)-1-(3,4-Difluorbenzyl)-2-oxo-N-(3-oxo-3-((2-oxo-3-(thiophen-2-ylmethylen)indolin-5-yl)amino)propyl)-1,2-dihydropyridin-3-carboxamid, (Z)-N-(3-((3-((1H-Imidazol-5-yl)methylen)-2-oxoindolin-5-yl)amino)-3-oxopropyl)-1-(3,4-difluorbenzyl)-2-oxo-1,2-dihydropyridin-3-carboxamid, (E/Z)-1-(3,4-Difluorbenzyl)-N-(3-((3-(4-fluorbenzyliden)-2-oxoindolin-5-yl)amino)-3-oxopropyl)-2-oxo-1,2-dihydropyridin-3-carboxamid, (Z/E)-N-(3-((3-((1H-Imidazol-2-yl)methylen)-2-oxoindolin-5-yl)amino)-3-oxopropyl)-1-(3,4-difluorbenzyl)-2-oxo-1,2-dihydropyridin-3-carboxamid, (Z)-N-(3-((3-((1H-Imidazol-5-yl)methylen)-2-oxoindolin-5-yl)carbamoyl)phenyl)-1-(3,4-difluorbenzyl)-2-oxo-1,2-dihydropyridin-3-carboxamid, (E/Z)-1-(3,4-Difluorbenzyl)-2-oxo-N-(3-((2-oxo-3-(thiophen-2-ylmethylen)indolin-5-yl)carbamoyl)phenyl)-1,2-dihydropyridin-3-carboxamid, (Z)-N-(4-((3-((1H-Imidazol-5-yl)methylen)-2-oxoindolin-5-yl)amino)-4-oxobutyl)-1-(3,4-difluorbenzyl)-2-oxo-1,2-dihydropyridin-3-carboxamid und (E/Z)-1-(3,4-Difluorbenzyl)-2-oxo-N-(4-oxo-4-((2-oxo-3-(thiophen-2-ylmethylen)indolin-5-yl)amino)butyl)-1,2-dihydropyridin-3-carboxamid besteht.
 
16. Verbindung gemäß Anspruch 15, wobei die Verbindung ausgewählt ist aus der Gruppe (Z)-N-(2-((3-((1H-Imidazol-5-yl)methylen)-2-oxoindolin-5-yl)amino)-2-oxoethyl)-1-(3,4-difluorbenzyl)-2-oxo-1,2-dihydropyridin-3-carboxamid, (Z)-(R)-N-(2-((3-((1H-Imidazol-5-yl)methylen)-2-oxoindolin-5-yl)amino)-2-oxo-1-phenylethyl)-1 -(3,4-difluorbenzyl)-2-oxo-1,2-dihydropyridin-3-carboxamid, und (Z)-(R)-N-(2-((3-((1H-Imidazol-2-yl)methylen)-2-oxoindolin-5-yl)amino)-2-oxo-1-phenylethyl)-1-(3,4-difluorbenzyl)-2-oxo-1,2-dihydropyridin-3-carboxamid, (Z)-N-(3-((3-((1H-Imidazol-5-yl)methylen)-2-oxoindolin-5-yl)carbamoyl)phenyl)-1-(3,4-difluorbenzyl)-2-oxo-1,2-dihydropyridin-3-carboxamid und (Z)-N-(4-((3-((1H-Imidazol-5-yl)methylen)-2-oxoindolin-5-yl)amino)-4-oxobutyl)-1-(3,4-difluorbenzyl)-2-oxo-1,2-dihydropyridin-3-carboxamid.
 
17. Verbindung gemäß Anspruch 14, wobei die Verbindung von (Z)-N-(2-((3-((1H-Imidazol-5-yl)methylen)-2-oxoindolin-5-yl)amino)-2-oxoethyl)-1-(3,4-difluorbenzyl)-2-oxo-1,2-dihydropyridin-3-carboxamid ist.
 
18. 2-Oxo-1,2-dihydropyridin-3-carboxamid-Verbindung gemäß einem der Ansprüche 11-17 zur Verwendung als Medikament.
 
19. Pharmazeutische Zusammensetzung, umfassend eine 2-Oxo-1,2-dihydropyridin-3-carboxamid-Verbindung gemäß einem der Ansprüche 11-18 und einen pharmazeutisch annehmbaren Träger.
 
20. 2-Oxo-1,2-dihydropyridin-3-carboxamid-Verbindung gemäß einem der Ansprüche 11-17 zur Verwendung bei der Behandlung von Pathologien, die einen Hemmer des PDK1-Enzyms erforderlich machen.
 
21. 2-Oxo-1,2-dihydropyridin-3-carboxamid-Verbindung zur Verwendung gemäß Anspruch 20, wobei die Pathologie aus der Gruppe ausgewählt ist, die aus Diabetes, neurodegenerativen Erkrankungen wie Alzheimer-Erkrankung und Prionenkrankheiten und Tumoren wie Brust- und Bauchspeicheldrüsenkrebs und Glioblastom besteht.
 
22. 2-Oxo-1,2-dihydropyridin-3-carboxamid-Verbindung zur Verwendung gemäß Anspruch 21, wobei die Pathologie ein Krebs, vorzugsweise Glioblastom (GBM), ist.
 


Revendications

1. Un composé 2-oxo-1,2-dihydropyridine-3-carboxamide de Formule (I)

dans lequel

m est 0 ou 1

n est 0 ou 1

A est sélectionné dans le groupe constitué de (-NH-CO-CH2-), (-NH-CO-CH(Ph)-), (-NH-CO-CH2-CH2-), (-NH-CO-CH2-CH2-CH2-) et (-NH-CO-Ph-) ; et

B est CH-D, où D est sélectionné dans le groupe constitué de thiényle, phényle, imidazolyle, étant facultativement substitué en D par un halogène,

ou un sel pharmaceutique de celui-ci pour une utilisation dans le traitement de pathologies nécessitant l'utilisation d'un inhibiteur de l'enzyme PDK1.
 
2. Le composé pour l'utilisation de la revendication 1, dans lequel m est 0 et n est 1.
 
3. Le composé pour l'utilisation de la revendication 1, dans lequel m est 1 et n est 1.
 
4. Le composé pour l'utilisation de la revendication 1, dans lequel A est (-NH-CO-CH2-CH2-CH2-), (-NH-CO-CH2-CH2), ou (-NH-CO-Ph-) ou (-NH-CO-CH(Ph)-).
 
5. Le composé pour l'utilisation de la revendication 4, dans lequel A est (-NH-CO-CH2-) ou (-NH-CO-CH2-CH2).
 
6. Le composé pour une utilisation de l'une quelconque des revendications 1, 4 à 5 dans lequel n est 1 et B est CH-D, où D est imidazolyle, préférablement 1H-imidazol-5-yl.
 
7. Le composé pour l'utilisation de la revendication 1, dans lequel ledit composé est sélectionné dans le groupe constitué de (Z)-N-(3-((1H-imidazol-5-yl)méthylène)-2-oxoindoline-5-yl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide, 1-(3,4-difluorobenzyl)-2-oxo-N-(2-oxo-2-((2-oxoindoline-5-yl)amino)éthyl)-1,2-dihydropyridine-3-carboxamide, (E/Z)-1-(3,4-difluorobenzyl)-2-oxo-N-(2-oxo-2-((2-oxo-3-(thiophén-2-ylméthylène)indoline-5-yl)amino)éthyl)-1,2-dihydropyridine-3-carboxamide, (Z)-N-(2-((3-((1H-imidazol-5-yl)méthylène)-2-oxoindoline-5-yl)amino)-2-oxoéthyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide, (Z)-(R)-N-(2-((3-((1H-imidazol-5-yl)méthylène)-2-oxoindolin-5-yl)amino)-2-oxo-1-phényléthyl)-1-(3,4-difluorobenzyl)-2-oxo-1 ,2-dihydropyridine-3-carboxamide, (Z)-(R)-N-(2-((3-((1H-imidazol-5-yl)méthylène)-2-oxoindoline-5-yl)amino)-4-oxobutyl)-1-(3,4-difluorobenzyl)-2-oxo-1 ,2-dihydropyridine-3-carboxamide, (E/Z)-1-(3,4-difluorobenzyl)-2-oxo-N-(3-oxo-3-((2-oxo-3-(thiophén-2-ylméthylène)indoline-5-yl)amino)propyl)-1,2-dihydropyridine-3-carboxamide, (Z)-N-(3-((3-((1H-imidazol-5-yl)méthylène)-2-oxoindoline-5-yl)amino)-3-oxopropyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide, (E/Z)-1-(3,4-difluorobenzyl)-N-(3-((3-(4-fluorobenzylidène)-2-oxoindoline-5-yl)amino)-3-oxopropyl)-2-oxo-1,2-dihydropyridine-3-carboxamide, (Z/E)-N-(3-((3-((1H-imidazol-2-yl)méthylène)-2-oxoindoline-5-yl)amino)-3-oxopropyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide, (Z)-N-(3-((3-((1H-imidazol-5-yl)méthylène)-2-oxoindoline-5-yl)carbamoyl)phényl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide, (E/Z)-1-(3,4-difluorobenzyl)-2-oxo-N-(3-((2-oxo-3-(thiophén-2-ylméthylène)indoline-5-yl)carbamoyl)phényl)-1,2-dihydropyridine-3-carboxamide, (Z)-N-(4-((3-((1H-imidazol-5-yl)méthylène)-2-oxoindoline-5-yl)amino)-4-oxobutyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide et (E/Z)-1-(3,4-difluorobenzyl)-2-oxo-N-(4-oxo-4-((2-oxo-3-(thiophén-2-ylméthylène)indolin-5-yl)amino)butyl)-1,2-dihydropyridine-3-carboxamide.
 
8. Le composé pour l'utilisation de la revendication 7, dans lequel ledit composé est sélectionné dans le groupe (Z)-N-(2-((3-((1H-imidazol-5-yl)méthylène)-2-oxoindoline-5-yl)amino)-2-oxoéthyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide, (Z)-(R)-N-(2-((3-((1H-imidazol-5-yl)méthylène)-2-oxoindoline-5-yl)amino)-2-oxo-1-phényléthyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide, (Z)-(R)-N-(2-((3-((1H-imidazol-5-yl)méthylène)-2-oxoindoline-2-yl)amino)-2-oxo-1-phényléthyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide, (Z)-N-(3-((3-((1H-imidazol-5-yl)méthylène)-2-oxoindoline-5-yl)carbamoyl)phényl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide, et (Z)-N-(4-((3-((1H-imidazol-5-yl)méthylène)-2-oxoindolin-5-yl)amino)-4-oxobutyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide.
 
9. Le composé pour l'utilisation de la revendication 8, dans lequel le composé de est (Z)-N-(2-((3-((1H-imidazol-5-yl)méthylène)-2-oxoindolin-5-yl)amino)-2-oxoéthyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide.
 
10. Le composé pour une utilisation de l'une quelconque des revendications 1 à 9, dans lequel la pathologie qui nécessite un inhibiteur de PDK1 est un cancer, préférablement le glioblastome.
 
11. Un composé 2-oxo-1,2-dihydropyridine-3-carboxamide de Formule (II)

dans lequel

n est 0 ou 1

B est CH-D, où D est sélectionné dans le groupe constitué de thiényle, phényle, imidazolyle, étant facultativement substitué en D par un halogène ; et

A est sélectionné dans le groupe constitué de (-NH-CO-CH2-), (-NH-CO-CH(Ph)-), (-NH-CO-CH2-CH2-), (-NH-CO-CH2-CH2-CH2-) et (-NH-CO-Ph-) ou un sel pharmaceutique de ceux-ci.


 
12. Le composé de la revendication 11, dans lequel A est sélectionné dans le groupe constitué de (-NH-CO-CH2-), (-NH-CO-CH2-CH2-), (-NH-CO-CH2-CH2-CH2-) et (-NH-CO-Ph-).
 
13. Le composé de la revendication 12, dans lequel A est (-NH-CO-CH2-).
 
14. Le composé de l'une quelconque des revendications 11 à 13, dans lequel n est 1 et B est CH-D, où D est imidazolyle, préférablement 1H-imidazol-5-yl.
 
15. Le composé de la revendication 11, dans lequel ledit composé est sélectionné dans le groupe constitué de (E/Z)-1-(3,4-difluorobenzyl)-2-oxo-N-(2-oxo-2-((2-oxo-3-(thiophén-2-ylméthylène)indoline-5-yl)amino)éthyl)-1,2-dihydropyridine-3-carboxamide, (Z)-N-(2-((3-((1H-imidazol-5-yl)méthylène)-2-oxoindoline-5-yl)amino)-2-oxoéthyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide, (Z)-(R)-N-(2-((3-((1H-imidazol-5-yl)méthylène)-2-oxoindoline-5-yl)amino)-2-oxo-1-phényléthyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide, (Z)-(R)-N-(2-((3-((1H-imidazol-5-yl)méthylène)-2-oxoindoline-2-yl)amino)-2-oxo-1-phényléthyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide, (E/Z)-1-(3,4-difluorobenzyl)-2-oxo-N-(3-oxo-3-((2-oxo-3-(thiophén-2-ylméthylène)indoline-5-yl)amino)propyl)-1,2-dihydropyridine-3-carboxamide, (Z)-N-(3-((3-((1H-imidazol-5-yl)méthylène)-2-oxoindoline-5-yl)amino)-3-oxopropyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide, (E/Z)-1-(3,4-difluorobenzyl)-N-(3-((3-(4-fluorobenzylidène))-2-oxoindoline-5-yl)amino)-3-oxopropyl)-2-oxo-1,2-dihydropyridine-3-carboxamide, (Z/E)-N-(3-((3-((1H-imidazol-2-yl)méthylène)-2-oxoindoline-5-yl)amino)-3-oxopropyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide, (Z)-N-(3-((3-((1H-imidazol-5-yl)méthylène)-2-oxoindoline-5-yl)carbamoyl)phényl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide, (E/Z)-1-(3,4-difluorobenzyl)-2-oxo-N-(3-((2-oxo-3-(thiophén-2-ylméthylène)indoline-5-yl)carbamoyl)phényl)-1,2-dihydropyridine-3-carboxamide, (Z)-N-(4-((3-((1H-imidazol-5-yl)méthylène)-2-oxoindoline-5-yl)amino)-4-oxobutyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide et (E/Z)-1-(3,4-difluorobenzyl)-2-oxo-N-(4-oxo-4-((2-oxo-3-(thiophén-2-ylméthylène)indolin-5-yl)amino)butyl)-1,2-dihydropyridine-3-carboxamide.
 
16. Le composé de la revendication 15, dans lequel ledit composé est sélectionné dans le groupe (Z)-N-(2-((3-((1H-imidazol-5-yl)méthylène)-2-oxoindoline-5-yl)amino)-2-oxoéthyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide, (Z)-(R)-N-(2-((3-((1H-imidazol-5-yl)méthylène)-2-oxoindoline-5-yl)amino)-2-oxo-1-phényléthyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide et (Z)-(R)-N-(2-((3-((1H-imidazol-2-yl)méthylène)-2-oxoindoline-5-yl)amino)-2-oxo-1-phényléthyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide, (Z)-N-(3-((3-((1H-imidazol-5-yl)méthylène)-2-oxoindoline-5-yl)carbamoyl)phényl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide, et (Z)-N-(4-((3-((1H-imidazol-5-yl)méthylène)-2-oxoindolin-5-yl)amino)-4-oxobutyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide.
 
17. Le composé de la revendication 14, dans lequel le composé de est (Z)-N-(2-((3-((1H-imidazol-5-yl)méthylène)-2-oxoindolin-5-yl)amino)-2-oxoéthyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide.
 
18. Un composé de 2-oxo-1,2-dihydropyridine-3-carboxamide de l'une quelconque des revendications 11 à 17 pour une utilisation en tant que médicament.
 
19. Une composition pharmaceutique comprenant un composé 2-oxo-1,2-dihydropyridine-3-carboxamide de l'une quelconque des revendications 11 à 18 et un véhicule pharmaceutiquement acceptable.
 
20. Un composé 2-oxo-1,2-dihydropyridine-3-carboxamide de l'une quelconque des revendications 11 à 17 pour une utilisation dans le traitement de pathologies qui nécessitent un inhibiteur de l'enzyme PDK1.
 
21. Le composé 2-oxo-1,2-dihydropyridine-3-carboxamide pour l'utilisation de la revendication 20, dans lequel la pathologie est sélectionnée dans le groupe constitué du diabète, de maladies neurodégénératives telles que les maladies d'Alzheimer et à prions, et les tumeurs telles que les cancers du sein et du pancréas et le glioblastome.
 
22. Le composé 2-oxo-1,2-dihydropyridine-3-carboxamide pour l'utilisation de la revendication 21, dans lequel la pathologie est un cancer, préférablement le glioblastome (GBM).
 




Drawing
























REFERENCES CITED IN THE DESCRIPTION



This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description




Non-patent literature cited in the description